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Abstract 
 
The purpose of this research is to obtain a better understanding of how 
clustering approach could affect the competitiveness of the pharmaceutical 
companies in Palestinian. 
This study is a descriptive exploratory study, the researcher had used 
qualitative methods, and the researcher had used three tools to collect 
information, structured interviews, semi-structured interviews, and a 
documentary analysis. The researcher had done an onsite visits for the four 
factories which enabled him to observe the operations processes, 
 
The interviews questions were developed in order to measure the current 
clustering situation of the companies and their competitive advantages, the 
researcher had collected the data from the middle managers at each 
company. 
Cross tabulations and desegregations features have been used to analyse 
data, and to enrich the results to get a better defining of the findings. 
Qualitative data and weighting criteria were developed and explored to read 
the data in depth. 
The researcher found that the Palestinian pharmaceutical companies don’t 
apply the clustering concept, while they play as a potential innovative cluster, 
so the researcher recommended the companies to work as a cluster, where 
this will enhance their competitiveness. 
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CHAPTER ONE 
Introduction 
1.1 Overview 
 
The pharmaceutical industrial sector is considered as one of the pillar industries in the 
Palestinian economy. The industry boomed after events in 1967 resulted in closed 
borders with the Arab world, where it was established with small laboratories to become 
now as sophisticated manufacturers. The Palestinian pharmaceutical industrial sector 
consists of five major manufacturers, which have an about 50% of the local market 
share, in addition to some exports to other markets (PNA, 2011). 
This research aims to study clustering which is an aggregation of related firms, or 
supplier that exist in a specific geographic area, and linked together through some 
common interdependencies to supply a related group of products or services (Porter, 
1990), and investigates how clustering could enhance the competitiveness of the 
industry, and answers the questions about the effect of industry clusters on companies' 
competitiveness. Many studies have indicated that clustering play an important role in 
improving the competitiveness of the industry and its product quality (Porter, 1990), 
(Najib et al., 2011), (Zhang & Luo, 2014).  
Nowadays companies are striving to obtain an advantage over their competitors by 
providing distinct products and services due to the easy access to know-How 
knowledge, increase of competition in the markets. Distinction could be attained by 
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applying one or more of the following approaches "strategies": higher quality of products 
and services; meeting special needs of market segments; and providing products and 
services at a lower price (McLeod & Schell, 2006).  
In order to compete nowadays within the new globalisation, companies must design and 
offer better products and services and improve themselves (Taj & Morosan, 2011). 
Every company has to have one of the competitiveness strategies, either to deliver 
higher quality products, or to concentrate at a significant lower cost in order to achieve a 
competitive advantage through the market. According to Porter (1990) Industrial 
competitive advantages could be created by clustering which will affect all of the firms 
within such an area, whereas such competitive advantages could be not possible to be 
created by a single firm alone.  
 Indeed, companies should make decisions and implement the clustering concept 
that eventually will have an impact on their performances. To do so effectively, they 
need enhance the relationships within the clusters and to access strategic resources, 
knowledge, technologies, information, and infrastructures that will create positive effects 
(Hoffmann et al., 2011). 
 
 1.2 Research Rationale 
Industrial clusters which are a specific type of clusters that are identified by its industrial 
related activities are considered as a network-based industrial system, that aims for 
adapting and fast changing the markets and technologies to the whole organization 
(Niu, 2012). As many countries, governments, and planners are driving the formation of 
4 
 
the industry cluster because clusters are generating external benefits geographic 
proximity such as cost savings that result from lower input costs and increased 
productivity  (Marshall, 1890)  
Pharmaceutical companies working in Palestine must look for new approaches to be 
implemented which will help them to reduce costs and increase productivity. In other 
words increase their competitiveness in the markets, therefore this research will 
highlight on the extent of clustering on competitiveness of the pharmaceutical industrial 
companies in Palestine as a developing country.  
The Palestinian pharmaceutical companies manufacture medicines in a very restricted 
ways depending on its capabilities, which could be summarized into two main 
categories, which are: production of formulations from pharmaceutical starting 
materials, and repackaging of finished dosage forms, while it lacks the capabilities of 
research and development for discovering new active substances, and Production of 
pharmaceutical starting materials. (PNA, 2011). 
All of the pharmaceutical starting materials that are used in the pharmaceutical industry 
are imported separately and specially for each manufacturer, and can't be used by other 
manufacturers. From an another point it is clear that the Palestinian pharmaceutical 
industry market, has all local manufacturers, where there is no any multinational 
pharmaceutical companies currently manufacture medicines locally. (PNA, 2011). And 
the percentages of exportation to the other markets are so limited due to the difficulty of 
penetration of other markets. (USAID & ICC palestine, 2013) 
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The companies which will be the subject of this study are the human 
pharmaceutical industries, where they are taken according to the Ministry Of Health 
(MOH) registration information. These firms are sorted in the following table 1.1: 
 
 
 
 
Table 1.1: Palestinian Pharmaceutical Companies 
No. Manufacturer location Date of 
establishment 
1 Birzeit Pharmaceutical Company  Ramallah 1973 
2 Jerusalem Pharmaceutical Company Ramallah 1969 
3 Dar Al-Shifa'a for the Manufacturing of 
Pharmaceuticals. (PHARMACARE)  
Ramallah 1986 
4 Chemical Jordanian Factory company Bet Jalla 1969 
5 The Middle East Pharmaceutical and 
Cosmetics Laboratories Ltd. (MEGAPHARM ) 
Gaza 1981 
Source: Palestine National Authority, pharmaceutical country profile (PNA, 2011). 
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1.3. Conceptual Model 
This Thesis concentrates on assessing the existing situation in the Palestinian 
pharmaceutical industry sector, whether it applies the clustering concept or no, or what 
is the current situation inside this sector concerning clustering. And also evaluates the 
comprehensive competitiveness of the Palestinian pharmaceutical companies. In order 
to know what is the effect of clustering on the companies' competitiveness, and what is 
the indicators which gives the best competitiveness, In order to sustain them, and which 
give the lowest competitiveness, in order to enhance them. 
The theoretical framework consists of two main phases, clustering assessment, and 
competitiveness assessment, as shown in the figure below, Fig 2.3. The contents of 
each phase are described below. 
 
Fig 1.1 
Conceptual framework 
 
1- Clustering assessment. 
As seen in fig 2.3 the clustering is the independent variable, where it could be assessed 
by the availability of clustering two main components; which are 1) cluster strategic 
resources, such as: access to HR, knowledge, technology infrastructure, capital 
resources, etc., and 2) cluster relationships, such as: geographic concentration, vertical 
integration, horizontal cooperation, and resource sharing. 
 
All of the 
competitiveness 
indicators 
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2- Competitiveness assessment. 
 
Literature has highlighted a number of firm's-specific factors, and models, in order to 
assess the competitiveness of the firms which is the dependent variable. However, the 
researcher had decided to apply the multiple indicator approach, where the indicators 
which have been selected to assess companies' competitiveness are based on the 
value chain model (Porter, 1985), in addition to the diamond model (Porter, 1990). Thus, 
the competitiveness indicators which will be studied in this thesis will be human 
resources, technological resources, technology & development, inbound logistics, 
outbound logistics, production and operation, services, marketing & sales, margin, firms' 
infrastructure, procurements of raw materials, support activities, and policy support. 
Each one of those indicators which are listed in table 2.3 represents a competitiveness 
point, and the company comprehensive competitiveness will be the summation of all of 
these indicators. 
Table 2.3 firms' competitiveness indicators 
Human resources Technological resources Inbound logistics 
Outbound logistics Operation Services 
Marketing & Sales Margin Firms' infrastructure 
Procurements Support activities Policy support 
 
On the other hand, the competitiveness will also be measured through analysing the 
financial indicators of the companies, such as profit, operating profits, and market share.  
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1.4 Research Questions and Objectives 
Objectives:   
The main objectives of this research are to measure the effect of clustering on 
Competitiveness in the selected Palestinian companies. Where the researcher chose 
Four Pharmaceutical Companies in Palestine as the population of the study in order to 
identify the research links between the Clustering and the Competitiveness with the 
context of the selected companies, based on the porter‘s diamond model, which is 
competitiveness assessment tool, that give a clear view about all the factor that affect 
the competitiveness, whether it were internal or even external factors, a more detailed 
description is in the next chapter.  
 
Questions:  
The main research questions are: 
 To what extent does the Palestinian pharmaceutical industrial sector follow 
the clustering concept? 
 To what extent does the Palestinian pharmaceutical industrial sector play as a 
potential cluster? 
 How does the implementation of clustering concept enhance the 
competitiveness of the pharmaceutical companies? 
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1.5  Limitations and Obstacles 
 The Middle East Pharmaceutical and Cosmetics Laboratories Ltd. 
(MEGAPHARM ), was removed from the study due to the political situation 
there which may affect the research results, and the difficulty to reach the firm 
there. 
 Due to the high competency between the companies most of them said they 
have no disadvantages.  
 The interviews were made with the middle level management due to the 
difficulty in meeting the higher level management.  
 The number of firms is four, and this is a small number to implement just a 
quantitative research approach, so the qualitative approach was used. 
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1.6 Research structure 
Chapter one:  presents the introduction, rationale, objectives, conceptual model, 
and limitations.  
Chapter two: presents literature review which describes the clustering, 
pharmaceutical companies' situation, competitiveness, competitiveness assessment 
tools, and research structure. 
Chapter three:  describes in details the methods, methodology, population, data 
collection methods, data analysis techniques, and trustworthiness.  
Chapter four:  illustrates the data analysis of structured interviews, unstructured 
interviews, financial analysis, and answers of the research questions. 
Chapter five:  presents the conclusions, and recommendations.  
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2.1 INTRODUCTION 
This chapter presents a comprehensive literature review of existing research covering 
three areas. The first review is of Palestine pharmaceutical industry. The second review 
is of literature related to theories of clustering. It is here that we first present the 
definition of―clustering, clustering initiatives, etc. The third review is of literature related 
to theories of competitiveness. as well as address the competitiveness of business 
organisations A series of theories of competitiveness are summarised first. Then, a 
comparison of competition evaluation methods is made. Based on this review, a 
theoretical framework for the competitiveness of pharmaceutical industry in Palestine is 
proposed.  
 
2.2 Palestinian Pharmaceutical industry 
 
The Palestinian pharmaceutical industry was established as a result of the 
shortages of certain drugs in the Palestinian market after 1967 war, which leaded to the 
isolation of the West Bank and Gaza from the rest of the Arab world. It began by a 
group of pharmacists who decided to start very small pharmaceutical businesses. And 
today it consists of five respected companies. 
 
The firms which will be the subject of this study are the human pharmaceutical 
industries, where they are taken according to the MOH registration information. These 
firms are sorted in the following table 2.1: 
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Table 2.1: Palestinian Pharmaceutical Companies. 
No. Manufacturer location Date of establishment 
1 Birzeit pharmaceutical company  Ramallah 1973 
2 Jerusalem pharmaceutical company Ramallah 1969 
3 Dar Al-Shifa'a for the Manufacturing of 
Pharmaceuticals. (PHARMACARE)  
Ramallah 1986 
4 Chemical Jordanian factory company Bet Jalla 1969 
5 The Middle East Pharmaceutical and 
Cosmetics Laboratories Ltd. 
(MEGAPHARM ) 
Gaza 1981 
 
The Palestinian pharmaceutical sector is an important and a successful sector among 
the Palestinian industrial sectors. The pharmaceutical industry according to the 
Palestine Central Bureau of Statistics (PCBS) (2013), consists of nine firms, two of them 
have stopped working, the first is Al-Jalil company stopped at 2010, and the other is 
Gama company stopped at 2012 according to MOH, and there is two companies made 
a merger with another companies, as will be mentioned below. These firms despite of 
their low number if compared to the large numbers of another industrial firms, a total of 
16201 industrial firms in Palestine (PCBS, 2013). Contribute with 1.95% of the total 
industry's income PCBS (2013), While they contributes less than 1% to Gross Domestic 
Product (GDP) in 2006, This leads to understand that this sector is among the fastest 
growing industries in Palestine due to the duplication of its contribution of the 
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Palestinian GDP in less than 10 years despite of its low number of firms. This makes it a 
very promising industry. 
Below is a more detailed literature on each one of the four companies of the West Bank, 
which have been collected from the annual discloser reports of each one of the 
companies (2013), where the fifth company which is Megapharm, that exists in Gaza 
had been ignored from this study; due to the political and economical situation in Gaza, 
which makes it hard to compare its situation with the status of the companies in the 
West Bank. 
 
2.2.1 Jerusalem pharmaceutical co.: 
Jerusalem pharmaceutical company is a public joint stock company established in 1969 
and located at Ramallah, West-bank. The company operates in the fields of 
development, manufacturing and marketing of human pharmaceutical products and 
personal and household care, veterinary and agricultural products. The company 
produces more than 200 medicinal products of various forms, as well as more than 150 
of other products. The company has many facilities in Palestine, Jordan, and Algeria. It 
employs more than 350 employees. The company holds a good manufacturing practice 
(GMP) certification, and ISO9001 and ISO14001 certificates . 
Jerusalem Company is looking to be a leader in the field of pharmaceutical, cosmetics 
and personal home care at the local and regional levels, by contributing to the 
improvement of the overall health of people by offering the best prices with quality 
products in line with international standards. 
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The Company mission is to improve the quality of life, health and safety in the 
communities in which they serve by providing quality products, competitive prices, and 
facilitate access for the customers. They are working to be the first choice for 
customers. And consider their employees as a foundation stone in the continued 
development of the overall quality of their system. It also aims to access global markets 
with high quality products, competitive prices and excellent service. 
Beside the main headquarter Jerusalem Company has four other subsidiary one locally 
and three international. 
 
 Balsam Company : 
This branch is allocated at Ramallah region Industrial .Balsam joined Jerusalem in 
1995. It was allocated for the manufacture of personal care, detergents, perfumes, 
cosmetics, personal care products and veterinary medicines. It produces more than 
40 varieties of detergents and personal care products in different sizes include 
different production lines: (creams, liquids, sprays).it also produces a varieties of 
perfumes and deodorants, with distinction from the French Parour company. 
In 2004 a project was initiated to produce veterinary medicines through different 
production lines, including liquids, injections and powder according to international 
standards. 
 Jordan River for Pharmaceutical Industries : 
Situated in the region of Ain Albasha- Jordan, with a registered capital of 2,000,000 
16 
 
JD. This branch employee‘s 107 employees. The company markets its products in 
addition to the Jordan market to the Gulf markets, especially Saudi Arabia, UAE, 
Bahrain, and Kuwait. JRPI holds a good drug manufacturing GMP certification, and 
marketing authorization certificate of the Gulf Cooperation Council. GCC, beside ISO 
9001.1400 certificate. 
 Sobrodam : 
Sobrodam location is in the Boumerdes Ouled Moussa. Algeria . It was partially 
subsidized by Jerusalem Co. at the beginning of the year 2011. With 49% of its 
capital. And it‘s administrative is controlled by Jerusalem Co. by the Board of 
Directors. It is licensed by the Ministry of Health for the manufacture and production 
of solid preparations. Equipped with all the productivity and laboratory devices 
supporting the productive process and hardware. 
 Jerusalem-Varm company: 
This branch is situated in Sharaka area in the Algerian capital. The company was 
founded in 2006, and it is wholly owned by Jerusalem Pharmaceutical. 
 
2.2.2 Birzeit Pharmaceutical Company (BPC): 
Birzeit Pharmaceutical Company (BPC) is Palestine's manufacturer of generic 
medicines. With more than 300 products distributed among ten production lines and 
covering different therapeutic ranges. BPC targets all types of customers in the local 
Palestinian market. BPC market is not limited to the Palestinian Territory, the company 
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has export to different markets – mainly Algeria and East Europe. It employs more than 
300 employees 
BPC combines many factors in order to maintain its success. These factors include: 
obtaining the latest quality standards certificates such as GMP (Current Good 
Manufacturing Practices) and ISO quality systems, strong financial position of the 
company, highly educated and well trained staff members distributed among the 
different departments, management team with good experience and high credibility, 
many strategic investments and alliances; local and international, ongoing product 
development and market development initiatives, state of the art facilities with a total 
area of 16,000 square meters, modern production lines operating according to the latest 
technology in this industry, and approved suppliers of raw and packaging materials 
BPC was established in 1974 in Birzeit village, 10km north of Ramallah as a private 
shareholding company with a total capital investment of USD 150,000. In 1979 Birzeit 
Pharmaceutical Company became a public share holding company with a capital of 
USD 0.5 million. Latter in 1992 The Company merged with the third largest 
pharmaceutical company in Palestine, Palestine Medical Company, in addition to 
establishing Medix Company for Beauty Care. Medix represents a number of 
international Companies, such as Maybelline, Vichy and INDOLA. In 2001 BPC 
acquired ISO 9001 certification, one year latter BPC took over 73% of Eastern Chemical 
Company, and later in 2004, the remaining 27% was acquired. BPC acquired ISO 
14001 certification in 2004. In 2005 BPC became listed in Palestine Securities 
Exchange. Continuous investment in quality lead BPC to acquire GMP certification 
according to WHO standards in 2008. BPC doubles its export market share which 
18 
 
reflected on its revenues during 2010. 
BPC manufactures and markets generic products in almost all therapeutic fields 
including a variety of dosage forms, the company manufactures and markets 300 
products distributed among ten lines of production: Ampoules, Capsules, Tablets & 
Caplets, Syrups, Suspensions & Granules, Ophthalmic, Semi-solids, Powder vials, 
Suppositories and Powders. BPC's facilities are set on a total area of 16,000 square 
meters, equipped with modern production lines operating according to the latest 
technologies in this industry.     
 
2.2.3 Beit Jala Pharmaceutical: 
Beit Jalla Pharmaceutical Manufacturing Company– formerly Jordan Chemical 
Laboratory -. BJP is located in Beit Jalla /Palestine, few kilometers from Bethlehem. BJP 
conducts its operations in accordance with Good Manufacturing Practices (GMP) and is 
ISO 9001:2008 and ISO 14001:2004 certified. BJP employs more than 150 employees 
and produce more than 150 products. 
Their vision is to serve humanity in enabling a better and healthier quality of life. And 
their mission is to  
1. Manufacturing safe, pure, and effective branded generic drug pharmaceutical 
products in compliance with GMP regulations 
2. Fostering a culture of team work achievements. 
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Beit Jalla Pharmaceutical was established in 1969, it was designed to manufacture 
generic drug pharmaceutical products of very high quality to the domestic market. 
Production lines for tablets, capsules, ointments and creams, syrups and suspensions, 
and suppositories were installed. In 1978 the company started the production of four 
different types of eye drops that proved to be a success further on. In 1992, decision 
was taken to start building a state of the art facility in compliance with GMP guidelines 
and relevantly to refurbish the old facility, all with the aim to produce PURE, SAFE, and 
EFFECTIVE drug pharmaceutical products. 
2.2.4 Dar Al Shifa Pharmaceutical Industries PLC 
PLC was founded in 1986 and registered under Number (562600288) under the 
Companies Act No. 12 of 1964. The registered address of the company (administration 
offices And factories) is: Bitounia – Ramallah. PLC activities Includes as stated in its 
Memorandum of Association, manufacture, sale, distribution, import and export of drugs 
and cosmetics ,And veterinary chemicals and materials. 
During the years 2000 - 1999, PLC was looking to secure the necessary funding to 
complete its ambitious goal. At its new plant, and between different sources of funding 
for the company, "Dar Al Shifa" chose to get funding by to increase its paid up capital 
through an alliance with Mr. Michael Verdz and his family company owners "Gronnthal 
GMPH‖ from Germany.  
Besides improving the financial aspect of the company, "Dar Al Shifa" company aimed 
through this alliance to meet with the challenges of globalization. The agreement with 
the Germans partners give them two seats on the board of ―Dar Al Shifa " and that 
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attended a very important impact on the financial and administrative levels . And the 
most important thing to PLC which was addressed in this context, is technological 
support and training for ―Dar Al Shifa ". And give the right to ―Dar Al Shifa " for 
manufacture and distribution of some of the agreed products of" Gronnthal ", which led 
to accelerate growth in sales in the "Dar Al Shifa" In addition to improving quality and 
thus securing high ability to overcome the challenges of competition. 
In late 2011, Verdz / owners Gronnthal family company decided to reduce the share of 
investment in PLC, and thus the company's management decided later to add new 
partners which was Bank of Palestine Inc. and Rich Investment and Development, 
where their re proportion in the company were 5.83% and 3.9% each, respectively, of 
the total Shares of the company, and the German partner's share became 23.92% of 
the total shares of the company. 
During the first quarter of 2008, with the support of German partners, "Dar Al Shifa" 
Company got a European good manufacturing certificate (GMP) from the German 
Ministry of Health, which allows the company to market its pharmaceutical products in 
The European Union. Moreover, the company acquired in the same period the 
Palestinian GMP certification. The number of company employees is (273) employees. 
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2.3 Clusters, clusters initiatives, and industrial clusters 
In the recent years, clusters are considered to be an important factor in 
enhancing the economic development worldwide, where many governments and 
strategy development institutions regard clusters as potential drivers for the 
development of companies, and enterprises, and increase of innovation, and innovative 
activities within a specific area, or economic sector. (UNIDO, 2013) 
Such development of economy, and increasing and supporting of innovation, 
which is the main target of the clustering process, could be achieved through policies, 
and activities that aim to support the whole cluster are called cluster initiatives, and they 
are considered to be effective instruments in gathering and concentrating of the 
resources, funding, and technological requirements in the targeted cluster area with a 
high growth potential to spread beyond its current locations. (UNIDO, 2013) 
Clusters are seen as an important factor for the explanation of the empirical 
phenomenon of geographical concentration of economic and innovation activities that 
are related to each other, and as key drivers of competitiveness and innovation in a 
given region and therefore for the growth or increase / improve jobs and living 
conditions of the population (VLĂSCEANU, 2014). Many different cluster definitions 
exist, depending on the purpose and context in which they are used. However, in many 
of these definitions, there is no clear distinction between the definition of "cluster" and 
"cluster initiatives". This distinction should be clear, the cluster being considered as real 
phenomena and cluster initiatives as structures / entities that aim to build new clusters 
or its expansion. (Zahradník, 2012) 
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Clusters are a group of companies, specialized suppliers, service providers, firms in 
related industries, and associated institutions (e.g., universities, standards agencies, 
R&D centers, and trade associations) in particular fields that are co-located in a specific 
geographic regions and linked by interdependencies in providing a relate group of 
products and/or services (Porter, 1990, 1998), while Tallman et al., (2004) defined 
clusters as a geographically concentrated firms that function as strategic entities in the 
industry, and share a considerable interest to regional economic development agencies, 
corporate managers, international strategy scholars, and support institutions, etc.  
 
More generally, clusters can be defined as a group of companies, institutions and 
economic agents, which are located near each other and have reached a sufficient 
scale to develop specialized expertise, services, resources, suppliers and skills (Clipa et 
al., 2012). A common element in the cluster definitions is the aspect of a concentration 
of one or more sectors within a given region, as well as the emphasis on networking 
and cooperation between companies and other institutions in that cluster (Haviernikova, 
2013).  
 
On the other hand, cluster initiatives can be understood as "organized efforts to 
increase growth and competitiveness of clusters within a region, involving cluster firms, 
economic and political and / or the scientific community" (Sölvell et al., 2003). The 
cluster initiatives often play an important role as providers of services to support 
clustering. Cluster initiatives can be defined as a legal entity that supports, manages 
and directs a given cluster (Adumitroaei et al., 2013). 
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The concept of cluster and its economic benefits have been firstly described by Marshall 
(1890) by the concept of ―industrial districts‖, where the cluster is an agglomeration of 
companies that operate in the same industry sector in a well-defined and small 
geographical area, and mostly was an urban area, and the benefits are reduction of the 
transportation costs, access to more resources, a pool of qualified work force, and 
access to information. 
 
Since cluster is often related to the industry, both terms are combined with each other 
and formed the concept of industrial cluster, which is a concentrated area of technical, 
economic, human resource, knowledge, etc., which reflects the level of development of 
the enterprise, the comprehensive development of the region, and offers the 
environment to improve the innovation capacity and competitive ability in the region 
(Zhang & Luo, 2014).  
 
Industrial clusters could be defined also as national industries that are linked together 
through vertical buyer-supplier or horizontal (common customers, technology etc.) 
relationships. Industrial cluster is based on the economic, not territorial criteria. It 
presents a group of enterprises for which the membership inside the group is the 
important element to each firm for its competitiveness. (EC, 2002:3) 
 
Clusters gain tangible and intangible benefits due to its proximity in geographic location 
and its activities, such benefits could be access to specialized human resources and 
suppliers, knowledge spillovers, pressure for higher performance competition, and 
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learning from the close interaction with specialized customers and suppliers (Ketels, 
2003). Clusters also could be considered as one of the important sources for improving 
competitiveness of firms within cluster due to its potential for facilitating the 
development of market oriented and innovative behaviour. (Najib et al., 2011). 
  
According to Ketels (2003) Clusters could be classified into many dimensions: (1) the 
type of products and services they produce,  (2) the locational dynamics they are 
subject to, like some industries which are tied to their location due to its local market, or 
due to its natural resources, or that industries which are traded industries that serves 
markets in many regions and countries, (3) their stage of development which depends 
on the business environment that the cluster operates in. however  in other literatures 
clusters could be classified in many ways such as knowledge-driven clusters, trade-
driven clusters, low-and high-tech clusters, and geographic and non-geographic 
clusters. (Aylward & Glynn, 2005). 
 
Although the term of cluster becomes more popular recently, there is no unique or 
standard model of clusters, but each country and region has a different set of clusters, 
shaped by historical background, national characteristics, the strength of the knowledge 
base, size, R&D, connectedness, and share of innovative products  (Aylward & Glynn, 
2005). In addition to these types of clusters, Mytelka & Farinelli (2000) had pointed two 
main distinctions between cluster types. These are: 
1- Spontaneous groupings of firms, suppliers and public sector bodies around a 
growth industry. 
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2- Constructed clusters such as industrial parks and incubators, originating through 
policy mechanisms with specific objectives in mind.  
Mytelka & Farinelli (2000) had divided the spontaneous clusters into three useful 
categories: Informal, Organized and Innovative. Based on innovation measure. While 
Aylward & Glynn (2005)  had described these categories of clusters, such that the 
informal clusters are those where the firm size is small to medium, skill levels tend to be 
low, innovation levels are traditionally low, where the organized clusters could be found 
in niche industry sectors, like marine manufacturing and equipment and the 
microelectronic industry, this type have a higher measure of innovation, small and 
medium firms with a growing level of innovative activity, and relatively high levels of 
exports. And the third type is the most advanced one with large firm size, skill levels 
range across low, medium and high, linkage levels are medium to high, exports are 
high, but another core criterion the "cooperation" is poor. 
 
According to Long & Zhang (2011) in their literature, industrial clusters has many 
positive effects such as better access to the market and suppliers, human resources, 
and easy technology spillover know-how. While they say that the main advantage of 
clustering in developing countries with limited financial development is to overcome 
some financial obstacles that face firms within clusters. 
Hsu & Lai (2013) had argued that clustering is the trend of the future. Where industry 
clusters have experienced rapid growth over the past ten years. The pace has remained 
relatively fast despite the impact of the global financial crisis. In fact, clustering is one of 
the paths to the enhancement of companies' competitiveness. However, Hsu & Lai 
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(2013) had explained that companies within cluster gain a competitive advantage over 
other companies because it can benefit from the resources of the cluster, and cluster 
relationships that exist between parties within cluster. 
Based on the many definitions of cluster, cluster initiatives, and industrial clusters, the 
researcher had made the following comparison between the definitions, as in the tables 
below: 
 
Table 2.2: cluster definitions.  
No. Reference  Definition  
1 Marshall, 1890 An agglomeration of companies that operate in the same 
industry sector in a well-defined and small geographical 
area, and the benefits are reduction of the transportation 
costs, access to more resources, a pool of qualified work 
force, and access to information. 
2 Porter, 1990 A group of companies, specialized suppliers, service 
providers, firms in related industries, and associated 
institutions (e.g., universities, standards agencies, R&D 
centers, and trade associations) in particular fields that 
are co-located in a specific geographic regions and linked 
by interdependencies in providing a related group of 
products and/or services 
3 Tallman, 2004 Geographically concentrated firms that function as 
strategic entities in the industry, and share a considerable 
interest to regional economic development agencies, 
corporate managers, international strategy scholars, and 
support institutions, etc. 
 Clipa, 2012 Group of companies, institutions and economic agents, 
which are located near each other and have reached a 
sufficient scale to develop specialized expertise, services, 
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resources, suppliers and skills 
 
From the above table, it is clear that all of the definitions share common aspects related 
to the cluster meanings, which are:  
 Geographic location proximity. 
 Related industries, or service providers. 
 And share considerable interests and linked together through some 
interdependences.  
 
Table 2.3: cluster initiative definitions 
No. Reference  Definition  
1 Sölvell, 2003 Organized efforts to increase growth and competitiveness 
of clusters within a region, involving cluster firms, 
economic and political and / or the scientific community. 
2 Adumitroaei, 2013 A legal entity that supports, manages and directs a given 
cluster. 
 
From the table above, it is clear that cluster initiative is a management effort that aims to 
increase growth, and competitiveness of the cluster, and manage and direct the cluster. 
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Table 2.4: industrial cluster definitions 
No. Reference  Definition  
1 European  
Commission, 2003 
National industries that are linked together through vertical 
buyer-supplier or horizontal (common customers, 
technology etc.) relationships. 
2 Zhang, 2014 A concentrated area of technical, economic, human 
resource, knowledge, etc., which reflects the level of 
development of the enterprise, the comprehensive 
development of the region, and offers the environment to 
improve the innovation capacity and competitive ability 
 
From the table above, it is clear that industrial clusters are the industries in a specific 
area that are linked together through vertical and horizontal relationships, and it gives 
an indication on the development level of the area. And offers the environment for 
improvement and innovation.  
 
2.3.1 Industry cluster resources 
 
A cluster‘s set of valuable resources constitutes its potentially strategic resources, 
(Fensterseifer & Rastoin, 2013), where they also defines the strategic resource as a 
valuable resource which contributes to the value creation by clustered firms‖, and hence 
to their competitive advantage. Porter (1990) had described the cluster resources 
through his diamond which consists of four interconnected factors that illustrates the 
elements of cluster formation, these factors are the production conditions, demand 
conditions, related and supporting industries and firm strategies, and structure and 
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rivalry. Where production conditions consists of the main resources that gives the 
cluster an important competitive advantage, these are   "human resources", natural 
resources, knowledge resources, capital resources, and firm infrastructure.  
 
Fensterseifer & Rastoin (2013) had categorized the resources of wine clusters in five 
categories; institutional capital like professional associations, training centers, research 
centers, and technical assistance centers. Specialization capital such as specialized 
labour, equipment, consulting, spillover of knowledge and technological know-how. 
Social capital which indicate the quality of social interactions inside the cluster like 
horizontal and vertical interactions. Reputational capital like the quality of the wine and 
customer trust. And Natural capital that includes climate, soil, water, etc… 
 
Firms that exist in a geographic cluster takes the advantages of tangible and intangible 
resources available in the cluster through exchange and combination of resources, 
cluster firms are able to optimize, reduce costs and improve innovation using the 
intangible resources of the cluster such as knowledge resources, and increasing 
efficiency of the resources for cluster firms because exchange and combinations of 
resources enables firms to use resources possessed by others within the cluster, Li & 
Geng (2012) argue that the resources shared among the cluster are sorted into six 
categories: common reputation, intensity of exchange and combination of resources, 
mutual trust between firms, collective learning and knowledge-sharing, dense of 
competition, and participation and support of the local institutions. 
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ST. John & Pouder (2006) argue that some clusters are formed due to the availability of 
many restricted resources that are a key driver to the specific industry needs, and gives 
the cluster an industry identity, these resources could be:  
1- Physical resources such as coal fields in Pennsylvania, and oil 
industries in Gulf States.  
2- Labour with a unique skills and experiences. 
3- Abundant of low-cost labour and raw materials. 
4- And favourable climatic and soil conditions as in grape growing in the 
Napa Valley.  
And many other examples like steel, wine, furniture, carpet, etc., where cluster growth 
may be constrained by the capacity or availability of the key resources.  
On the other hand there are some clusters like photonics clusters in Tucson, Ottawa, 
and Tampa-Orlando, depends mostly on the technological development which gives it a 
technological identity. These clusters rely mainly on resources that give it an innovation 
and competitiveness advantages, such as knowledge, university research, and national 
laboratories. (ST. John & Pouder, 2006) 
In addition to that, Olson (1998) had demonstrated that technology based industries 
depend on four strategic resources which play the main role to the competitiveness of 
the cluster, that are 1) skilled workforce, 2) universities & R&D centers, 3) transportation 
and communication infrastructure to stay close to customers, and 4) high-quality life 
where many companies can gain a competitive advantage in recruiting highly skilled 
technicians, professionals, and other personnel if they can offer an exceptional place to 
live, as well as to work.  
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Clar et al. (2008) had also argues that companies within clusters principally benefit from 
cluster strategic resources which are: (1) specialized workers, (2) specialized suppliers 
and customers that is in other words the vertical supply chain infrastructure, (3) the 
specific infrastructure with training institutions, research and development organizations, 
and venture capital providing organizations etc. (4) and the spillover of knowledge.  
Hsu & Lai (2013) while studying the Effects of Industry Clusters on Company 
Competitiveness in Taiwan economic zones suggested that the main strategic 
resources that are required for clusters are (1) human resources; (2) knowledge 
resources, (3) technological infrastructure,  (4) capital resources, and (5) firm 
infrastructure. 
The researcher through his literature on the main cluster resources that are considered 
to benefit the firms, and companies within the cluster, refers to the research and 
definitions by Fensterseifer and Rastoin (2013), Porter (1990), Li and Geng (2012), ST. 
John & Pouder (2006), Olson (1998), Clar et al. (2008), and Hsu & Lai (2013) regarding 
industrial cluster resources, and constructs a list of key factors of the strategic 
resources of the industrial clusters, which are:  
 Specialized workers (human resources). 
 Abundant of low-cost raw materials. 
 Firm's infrastructure. 
 The specific infrastructure with training institutions, research and development 
organizations, and venture capital providing organizations etc. 
 And technology resources. 
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2.3.2 Industry cluster relationships 
 
All clusters are made up of a group of firms that work with and share common suppliers 
and distributors. While it consists of the firms and organizations which have a strong 
local networks of association and are looking to work as a group in a collaborative way 
to achieve the best results of the regional industries development and to penetrate new 
export markets, because they share the same commonalities such as core 
competencies, strategic infrastructure, regional risk and economic development 
opportunities (Enright & Roberts, 2001). 
 
Anderson (1994) had classified the relationships between companies within the 
industrial cluster into three main categories, which are: 1. buyer-supplier relationships, 
which exist between companies that produce goods and services from earlier stages to 
the final stages in the value-adding chain 2. competitor and collaborator 
relationships,  exists between companies that produce the same or similar goods and 
services, because they could share information which leads to improve their 
innovativeness, such as new processes, and work together to build new associations, 
and alliances that help all of them. and 3. shared-resource relationships.  These 
relationships exist  between firms in the cluster that deal with the same sources of raw 
materials, technology, human resources, etc. Anderson also indicated that these 
relationships benefits from geographic proximity. 
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Jacobs & De Man (1996) reviewed the research literature of the cluster concept and 
pointed out six dimensions that represent the major activities and interactions between 
firms within cluster. Which could be illustrated as follow: 
 
1- Horizontal, Which indicate to the direct competitors in the same or related 
industries 
2- Vertical, firms that exist in the several phases of the supply chain from up to 
bottom. 
3- Lateral, firms in different industries that relies on common resources. 
4- Technological, firms in a collection of industries that share a basic technology 
5- Focal, firms are concentrated around a central entity such as, research center, or 
educational institution. 
6- Network quality, which indicates to the degree of cooperation that exist between 
firms within cluster. 
 
Boari (2001) Had discussed the growth of the industrial clusters and argued that it 
consists of different stages with different roles played by focal firms and suppliers inside 
the clusters, these stages are: unplanned vertical relationships with suppliers, in the 
second stage these relationships becomes planned, in the third stage the horizontal 
relationships among suppliers becomes relevant, and the fourth is the increase in the 
hierarchical character of the cluster. While she also argues that these relationships 
between firms and suppliers tend to foster cooperation and trust between them. And 
they do more investments in a common specific assets, because of their mutual 
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expectation of future profits, awareness of switching costs, and realization of the role of 
their relationship in the process of new product development. 
 
Hsu & Lai (2013) had reviewed many studies about cluster relationships among 
companies and summarized these relationships into four points; that are the geographic 
concentration of manufacturers, vertical integration from upstream to downstream, 
horizontal cooperation and competition, and resource-sharing relationships. 
 
According to Newlands (2003) the most important advantages to firms within clusters 
comes from the horizontal relationships which particularly focus on competition and 
cooperation, Collaboration between firms can help them become more innovative 
helping them to capture and sustain their competitive advantages, and to overcome the 
negative effects of corrosive competition, in other words there is no necessary 
contradiction between collaboration and competition, but cooperation  will increase the 
degree of competition within industries. 
The researcher had adopted four types of cluster relationships in this thesis based on 
the aforementioned literature, where these relationships are described in the table 
below, in addition to the corresponding definitions of these relations that mentioned in 
the literature. 
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Table 2.5 Cluster Relationships 
# Relationship type Anderson 1994 Jacobs & De Man 
1996 
Boari 2001 Hsu & Lai 
2013 
1 Vertical integration 
across supply 
chain 
buyer-supplier 
relationships 
Vertical between 
supply chain 
phases. 
Vertical 
relationships. 
Vertical 
integration 
2 Horizontal 
competition and 
cooperation 
competitor and 
collaborator 
relationships 
Horizontal between 
competitors, and 
network quality. 
Horizontal 
relationships. 
Horizontal 
competition 
and 
cooperation 
3 Resource sharing 
relationships 
shared-resource 
relationships 
Lateral, 
technological, and 
focal. 
Investments 
in common 
assets. 
Resource-
sharing 
4 Geographic 
proximity 
benefits from 
geographic 
proximity 
  Geographic 
concentration 
 
Table 2.5 shows that the clustering relationships are mainly four relationships, which are 
the vertical or could be called buyer-supplier relationships, the horizontal or could be 
called also competitor- collaborator relationships, resource sharing or any collaborative 
relationships, and finally geographic location proximity, which is the first part of the 
cluster definition.  
 
 
 
 
 
 
 
36 
 
2.4 Competitiveness 
 
Various studies have been conducted on the subject of competitiveness. These can be 
categorized into three levels: micro, meso, and macro. These can be further 
characterized as being applicable to organization competitiveness "micro level", 
industrial competitiveness "meso level", and national competitiveness "macro level" 
(Nelson, 1992). As mentioned by Man et al. (2002) whatever the levels of focus are, 
competitiveness is eventually concerned with the long-term performance of the subject 
relative to its competitors, the result of being competitive. 
Different definitions of competitiveness apply to these different levels. From a macro 
perspective, such that a national viewpoint, competitiveness enhances the prosperity of 
the nation by improving the real income of its citizens whose performance comprise the 
social, cultural, and economic variables in international markets  (Nelson, 1992). In early 
1990s, Porter developed a diamond framework to specify the role of the national 
environment in influencing the international competitiveness of an industry. Porter 
(1990) reveals that four attributes of the home country environment have an effect on 
the context which allows firms to gain and sustain competitive advantage. These are: 
factor conditions, demand conditions, related and supporting industries, and context for 
firm strategy and rivalry. In Porter‗s view, two exogenous factors, government and 
chance, influence the functioning of these four major determinants of the diamond, 
figure 2.1. 
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Figure 2.1 Porter's diamond 
Source: Porter (1990) 
 
From a micro-meso perspective, the concept of competitiveness at the company and 
industry levels has also been adopted in different contexts. Industrial competitiveness is 
considered as the ability of a company or industry to meet challenges posed by foreign 
competitors (Ketels, 2006). Najib et al. (2011) defined firm competitiveness as; "The 
degree to which a firm can, under free and fair market conditions, produce goods and 
services that meet the test of international markets while simultaneously maintaining or 
expanding the real incomes of its employees and owners." 
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Industry bodies and firms are supposed to understand and improve their 
competitiveness, as competitiveness is the key to the success or failure in a market 
economy (Porter,1990). Therefore, competitiveness at the firm level is mainly measured 
by the competitive capability of a firm to earn desired competed results (profits, and 
market share) and ensure its future development.  
The researcher in study decided to choose porter's model in order to assess the 
competitiveness of the industry, that is because this model covers the whole criteria that 
could affect the competitiveness of the firms, and the industry, starting from factor 
conditions, to the strategy of the firms, to demand and the status of the market, and 
ending by the surrounding environment from the physical infrastructure to the 
government and supporting policies. 
But because the focus of this study is the competitiveness of pharmaceutical 
companies, competitiveness was reviewed in more detail from a micro Perspective, 
such as organization or firm competitiveness. 
 
2.4.1 Corporate Competitiveness 
At the individual firm level competitiveness concept includes various disciplines such as 
comparative advantage, price competitiveness perspective, strategy and management 
perspectives, and the historical and socio-cultural perspectives (Man et al. 2002). 
Different micro perspectives of competitiveness have been proposed in existing 
literature. Flanagan et al. (2007) have reviewed and provided valuable insights into 
firms' competitiveness. They summarized three main schools of thought in corporate 
competitiveness, these are 1) competitive advantage and competitive strategy models 
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such as (Porter, 1980), 2) resource-based view (RBV) and core competence approach 
as (Barney, 1991), and 3) the strategic management approach like (Wheelen and 
Hunger 2002). 
First, Porter‗s theory for corporate competitiveness is characterized as the industrial 
organization view of competitive advantage (Flanagan et al. 2007), It was supposed that 
competitive advantage comes from the competitive strategy a firm adopts to neutralize 
threats or to exploit opportunities presented by the industry (Porter, 1980). Major 
components in Porter‗s theory are: 1) the five competitive forces model; 2) the three 
generic competitive strategies ―cost-leadership, differentiation, and focus on cost or 
differentiation‖; and, 3) the value chain.  
However, in analysing the competitiveness of firms, Porter‗s theory has been the 
dominant tool for the past two decades. Because it has various merits such as its 
simplicity, and its strong theoretical underpinnings (Miller & Dess, 1993), on the other 
hand, Porter‗s theory has got so much criticism due to its openness, for example it does 
not address the internal mechanisms by which a company converts the influence of a 
challenging external environment into useful internal abilities (Lado et al., 1992). 
Second, Resource-Based View ―RBV‖ assumes competitive advantage does not 
depend on market and industry structures but stems from the resources inside a firm 
(Flanagan et al. 2007). The resource-based competitiveness theory considers the 
corporation‗s unique resources as the source of its organisational core competitiveness 
(Barney, 2001), Barney (1991) classifies firm‗s resources into three categories: physical 
capital resources (such as plant, equipment), human capital resources (such as training, 
experience, judgment, intelligence, relationships, and insight of individual managers and 
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workers in a firm), and organizational capital resources (such as formal and informal 
planning, and the controlling and coordinating systems of a firm). 
According to Barney (2001), the resource-based view offers a useful framework to gain 
sustained competitive advantage. However, there are limitations on the resource-based 
view. Firstly, the resource-based theory is based on the incapacity to do an empirical 
study on measuring the performance. Because of the heterogeneity of firms, composing 
a homogeneous sample is hard or even impossible. Secondly, the resource-based view 
is focused on the internal organization of a firm and it does not consider the external 
factors like the demand side of the market. So even if a firm has the resources and the 
capabilities to gain a competitive advantage, it might be that there is no demand, 
because the model does not consider the ―customer‖. Thirdly, the resource-based view 
has a limited ability to make reliable predictions.  
However, Barney (2001) states that ―resource-based logic can help managers more 
completely understand the kinds of resources that help generate sustained strategic 
advantages, and help them use this understanding to evaluate the full range of 
resources their firm may possess, and then exploit those resources that have the 
potential to generate sustained strategic advantage". 
The third school of corporate competitiveness theory focuses on strategic management 
(Flanagan et al. 2007). As defined by Wheelen and Hunger (2012), strategic 
management refers to a set of managerial decisions and actions that determines the 
long-run performance of a corporation. It comprises some generic procedures such as 
environmental scanning, strategy formulation, strategy implementation, and evaluation 
and control (Wheelen & Hunger, 2012). The three generic strategies are approaches 
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that are frequently used. Interestingly, the evolution of strategic management theory has 
embraced Porter‗s theories and RBV as components (Wheelen & Hunger, 2012). 
Anyway, Flanagan et al. (2007) conclude that all three schools of theories are useful in 
their own way for achieving competitive advantage for firms and none of them on its 
own can fully explain a firms‗ competitiveness. 
The researcher had made the following comparison between the three strategies, as in 
the following table: 
Table2.6: competitiveness assessment schools 
Name competitive advantage and 
competitive strategy 
models 
Resource-based view 
(RBV) 
Strategic 
management 
approach 
Components 1) the five competitive 
forces model; 2) the three 
generic competitive 
strategies ―cost-leadership, 
differentiation, and focus 
on cost or differentiation‖; 
and, 3) the value chain. 
considers the 
corporation‗s unique 
resources as the source 
of its organisational 
core competitiveness 
 
set of managerial 
decisions and 
actions that 
determines the 
long-run 
performance of a 
corporation 
How it used simple competitiveness comes 
from: 
 physical capital 
 human capital 
 organizational 
capital 
Comprises of 
environmental 
scanning, strategy 
formulation, 
strategy 
implementation, 
and evaluation and 
control 
 
Criticism  Criticism on its openess limited ability to make Uses RBV and 
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reliable predictions porter theories as a 
components 
 
This study was designed based on the first school of corporate competitiveness 
theories, which is porter's theory ―the industrial organization view of competitive 
advantage‖, because it is an open theory, simple, have a strong theoretical 
underpinnings (Miller & Dess, 1993), and covers every part in the value adding chain of 
the industry, while the Resource-Based View ―RBV‖  have been not used because it 
assumes competitive advantage does not depend on market, and industry structures, 
while these are the most factors that affects the pharmaceutical industry, and it has a 
limited ability to make reliable predictions. On the other hand the third school which is 
the strategic management is so wide theory and uses Porter‗s theories and RBV as 
components of it.      
 
 
2.5 Competitive advantages of clusters 
Hsu & Lai (2013) suggested that industry clusters had an important effect on cluster's 
firms' performance, due to their proximity they have better exchange of goods and 
services, better access to the information which enhances their cooperation and 
competition, and better problem solving to the shared problems. Where SDAG (2001) 
illustrated that clusters lead to innovation because of its core characteristics of close 
collaboration and close competition, whereas cluster develops a new demand for new 
types of products and services will be created. Such demand will be supplied by the 
existing firms where the other demand will motivate for establishing new companies to 
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enter the market. In other words clustering gives the region a competitive advantage 
through having more innovation which lead to inject more capital, and raising the 
economic profit. 
Hsu & Lai (2013), and SDAG (2001) had measured the competitive advantages of 
clusters by measuring their effects on the company's performance, these effects are:  
Revenue increases, Operating profit increases, Operating cost decreases, Profitability 
improvements, Overall technology upgrades, Innovation and R&D. competency 
enhancements, and as an overall enhanced competitiveness. 
 
Schmitz (1995) illustrated that clusters build a competitive advantages in two ways, the 
first one is referred to as joint action and the second as collective action. Where joint 
actions are typically undertaken in cooperative efforts by firms inside the cluster, while 
the collective actions are not limited to firms but can involve them, and may even be led 
by other actors and entities of the cluster. Fensterseifer & Rastoin (2013) explained that 
collective actions refers to those actions that are economically or politically motivated for 
the benefit of the cluster as a whole such as  promotion of the region‘s products, and 
cluster-wide strategic planning, where these types of actions typically involve public 
agents and business associations. on the other hand, joint actions  involve firms within 
the cluster that strategically interact, horizontally or vertically, in order to share benefits 
that could be achieved in group working, such actions could be joint development, 
experimentation, co-production, joint purchasing of inputs, and joint marketing. 
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Clar et al. (2008) demonstrated that the cluster firms apply the concept of Marshallian 
external economies, due to its geographic proximity, and this fundamentally lower the 
transaction costs. And give the companies the opportunity to actively collaborate to 
benefit from joint activities such as: joint sourcing of materials, services etc. joint 
marketing activities, such as starting a cluster initiative to attract attention, new 
business, etc. and joint innovation activities, like starting an interactive learning process 
which could lead to unique localized capabilities (Prendergast, 1993). Maskell & 
Malmberg (1999) explained that companies build their competitiveness in interaction 
with localized capabilities, where these capabilities could be based on: 
1- The region's infrastructure and built environment. 
2- The available natural resources in the region. 
3- The region's specific institutional facilities. 
4- And the knowledge and skills available in the region. 
According to the literature of Yang & Wang (2008) cluster competence comes mainly 
from innovation, learning and sources integration, the ability of improving productivity 
and innovation performance, applying positive specialized effect, pushing positive 
externality and knowledge overflow, enhancing corporate coordination effect, and 
occupying global market share. Where they also discusses that cluster competence 
could be based on the size of many issues such as: knowledge flow, return on scale, 
increasing return, economic integration, market capacity, decreasing transaction costs, 
etc.  
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Clusters increase the competitiveness of all the cluster members and play an important 
role in the economic growth of the whole region, while this is possible because of the 
following reasons. (Stejskal & Hajek, 2012)   
1- clusters increase productivity through the possibility of having access to 
specialized inputs (including human capital), information, and institutions, 
2- clusters increase innovative capacities (due to competitiveness inside the cluster) 
3- clusters stimulate quick production and attract new firms to the cluster, 
4- Clusters make regional strategic planning of higher quality possible; this is 
caused by knowledge of the entrepreneur environment. 
Clusters also adds a competitive advantage to the industry by producing a conditions 
that leads to more developments and innovation, such conditions are: sheer pressure, 
peer pressure, competitive pressure, comparison between firms, better contact with the 
market needs, attraction of public institutions like investment in training and education, 
formation of new businesses, and good attraction of the related businesses. (Porter, 
1998) 
Finally the concept of clusters had become more obvious and attractive after Porter‘s 
Competitive Advantage of Nations (1990), where Porter highlighted that multiple factors 
beyond the ones internal to the firm may improve its performance in his diamond model 
figure 2.1. Which consists of four sets of interrelated forces that are brought forward to 
explain industrial dynamics. These are associated with factor input conditions, 
sophisticated local demand conditions, related and supported industries, and firm 
structure, strategy and rivalry (Andersson et al., 2004).  
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The four elements of Porter's (1990) diamond figure 2.1 represents the most important 
facets, which enables firms, or cluster to create their competitive advantages. Such 
factors are: (1) firm strategy, structure and rivalry, which indicates the nature of the firm, 
how it is organized, and managed, and its attitudes toward competition, market's 
institution, and the degree of competition in the main markets, etc. (2) Factor conditions 
–inputs-, this element indicates the input factors of the industry process, such as human 
resources, physical resources, administrative infrastructure, information and 
technological infrastructure, and other resources, etc. (3) Demand conditions, where 
this element indicates the sophisticated and demanding local customers, unusual local 
demand etc. (4) Related and supporting industries, such as presence of capable local 
based suppliers and competitive related industries. Other than four factors, two other 
factors, government and chance plays a vital role while shape up the competitiveness 
(Porter, 1990), (Ketels, 2006). 
 
2.6 Competitiveness assessment: 
Intense competition among industrial firms requires these firms to improve their 
competitiveness. Competition not only forces firms to improve themselves, but also 
exerts a direct positive impact on the competitiveness of the industry as whole. There 
has been some debate as to how the competitiveness of organizations should be 
measured and what factors affect their competitive performance. (Dess et al., 2010). 
Recognizing which factors primarily affect competitiveness remains debatable. 
Particularly, measuring only a single performance criterion such as profitability or 
financial indicators such as return on investment or return on assets is insufficient to 
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determine the excellence of an industry. A number of non-financial performance 
indicators are also important. These non-financial performance indicators include: 
overall customer satisfaction, productivity, performance in sales, growth of sales, market 
share, growth of market share, and overall competitiveness (Sirikrai & Tang, 2006). 
 
Man et al. (2002) suggested that three key aspects contributing to a firm‗s 
competitiveness which are: the internal firm factors, the external environment and the 
influence of the entrepreneur. The internal aspects of a firm‗s competitiveness, which 
are represented by the capital and resource dimensions, where the external 
environment is the availability of opportunities to generate increased long-term 
profitability inherent in the external environment. And the third aspect is the influence of 
the entrepreneur and the key player in the market. 
To measure the competitiveness of a company, the researcher should select the most 
appropriate approach to his case. Through reviewing the existing literature on 
competitiveness assessment approaches, two main approaches are the mostly used, 
which are the indicator approaches, and the modeling approaches. 
  
 
2.6.1 Indicator Approaches (IA) 
The indicator approach is widely used to assess the competitiveness of an organization 
or industry. It can be employed in one of two ways: the single indicator method and the 
multi-indicator method (Rappaport, 1983). Indicators such as profitability, organizational 
structure, knowledge management, cost advantage, HR management, innovation 
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capability, market share, total assets and profitability are often used to appraise the 
competitiveness of an organization from a specific perspective (Zhang et al., 2009). 
The method for adopting a single attribute to examine the competitiveness of an 
organizational is called the single indicator approach (SIA). The limitations of the SIA 
are obvious, because it can‗t be used to evaluate an organization's comprehensive 
competitiveness. 
To overcome this limitation, multiple indicators are used to assess the competitiveness 
of an organization from multiple perspectives. This method can precisely represent the 
overall competitiveness of an organization. To distinguish the relative importance of the 
individual contributors, each indicator is given a different weight. This is called the 
Weighted Summation (WS) method, which is a quantitative method (Rappaport, 1983). 
 
 
2.6.2  Modeling Approaches 
 
In addition to the indicator approach, many other methods have already been developed 
and used for measuring and assessment of the competitiveness of firms in different 
industries, modeling is an assessment method for organizational or company's 
competitiveness. A number of different models have been listed below with brief 
description.  
 
2.6.1.1 Value Chain Model (VCM) 
Value chain modeling was presented by Porter (1985) to examine the competitiveness 
of an organization based on the production process and it shows the organization as a 
sequential process of value creating activities. The VCM consists of two different 
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categories; primary and support activities, the primary activities include five major 
production processes, including: internal logistics; production; external logistics; 
marketing and post-sale services; and four support activities, comprising infrastructure 
such as administration, HR management, technology R&D and material procurement. 
The core principle of VCM is that an organization's competitiveness accumulates 
through conducting all these value adding activities. Therefore each activity is important 
and studied alone and should be taken in order to increase the overall competitiveness 
(Dess et al., 2010). 
 
2.6.1.2 Competence Pyramid Model (CPM) 
CPM was used at the first to assess the competitiveness of organizations in 
manufacturing (Walsh & Linton, 2001). Where in their research four aspects of an 
organization are applied to evaluate competitiveness: materials, fabrication and 
assembly, knowledge-based services and knowledge-embedded services. Each of 
these aspects had two dimensions: managerial capability, and technical competency. 
 
2.6.1.3 Portfolio Matrix Model (PMM) 
 
PMM was created by a leading consultant firms during the 1970s and early 1980s to 
analyze the competitive portfolio of a businesses, and products. PMM evaluates the 
competitiveness of a portfolio business organization from two dimensions: The strength 
of the business; and the attractiveness of the industry. The strength of the business is 
evaluated by indicators such as market share, productivity, profitability and customer 
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loyalty, while the attractiveness of the industry is determined by such indicators as 
potential market size and a predictable market growth rate (Udo-Imeh et al., 2012). 
 
2.6.1.4 Enterprise Model (EM) 
The enterprise model (EM) was used by Hatten & Rosenthal (1999) to analyze business 
functions and processes in order to understand the competitiveness of an organization. 
The model established a schematic network comprising horizontal and vertical axes 
which represent business processes and functions respectively. Horizontal units 
express business processes such as production, sales, logistics and post-sales service, 
while vertical units related to business functions, such as R&D, finance and marketing. 
The enterprise model provided a basis for measuring the competitiveness of an 
organization as well as identifying opportunities for leveraging its performance. 
 
2.6.1.5 Industrial Competitiveness Model (ICM) 
The industrial competitiveness model (ICM) measured the competitiveness of a 
manufacturer from an industry perspective (Oral, 1993). The ICM model considers 
competitiveness as a mathematical function of the firm‗s position in its operating 
industry. This includes its present position, present comparative position, potential 
position, and potential comparative position.  
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2.7 Selection of best competitiveness assessment method 
 
The effectiveness of application of a specific competitiveness assessment method will 
depend upon whether the principles of the method are suitable to the characteristics of 
the pharmaceutical industry,  
 Value chain model (VCM). 
The value chain model is considered suitable to find out the sources of competitiveness 
for pharmaceutical industry as pharmaceutical industry operates a complicated process 
which composes various value-added activities (Zhang et al., 2009). In addition to that, 
value chain approach has been considered traditionally effective in analysing the 
competitiveness and activities of production enterprises (Chiang & Trappey, 2007). 
 Portfolio matrix model (PMM) 
PMM model is for measuring the competitiveness level between different business 
activities from perspective of attractiveness and strength (Zhang et al., 2009), which 
means that this model could be used when the firm work in various fields, and want to 
study the competitiveness of each one alone, in order to help in making its strategic 
decisions. This means that it can't be considered applicable in analysing the 
competitiveness of pharmaceutical companies since this study focuses on one field 
"pharmaceutical industry", and aims to classify the competitiveness of each company, 
and study them. 
 Enterprises model (EM) 
EM helps organizations to identify competitive strategies by examining unique 
resources in the organizational functions and processes (Zhang et al., 2009). Since the 
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pharmaceutical industry is a high-tech industry which means it has a unique resources, 
this makes it applicable to the EM analysis. But the situation in Palestine, "where there 
is no intellectual rights and the production is almost by producing just generic products", 
makes the industry relies mainly on the production, not on high investments in R&D, or 
even in acquiring a unique resources, and this makes the EM not the preferred choice. 
 Industrial Competitiveness Model (ICM) 
ICM method presents a framework of integrating multiple attributes for assessing 
organizational competitiveness at an industry level through mathematical models. As for 
the macroscopic attributes (oral, 1993), so this method is considered not applicable for 
application in assessing pharmaceutical companies' competitiveness at enterprise level. 
 Indicator approaches (IA) 
Indicator approaches are divided into two approaches: First, single indicator approach 
which suggests adopting one indicator for measuring an organization‘s competitiveness. 
It is applicable to measure firm's competitiveness from a specific dimension but not a 
holistic view. However, the pharmaceutical industry's competitiveness is formed by 
many aspects, thus SIA is considered not effective in analysing its competitiveness. 
Second, multiple indicators approach which could be categorised into weighted 
summation and key competitiveness indicator, both methods are considered an 
effective  indicators and present a weighted index value for measuring firms' 
competitiveness, nevertheless, both of them are a quantitative methods. 
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By referring to the literature of the  assessment methods the researcher decided to use 
the a combination of the value chain model plus the indicator approaches, where the 
indicators that have been used are based on the porters diamond model, because it is 
the most convenient model that is designed to measure the competitiveness of the 
companies based on the production process, and it shows the company as a sequential 
process of value creating activities, where it measures these activities in detailed and 
separated form, which enables a deep understanding of  the strength and weakness 
points of the firm in all of its value adding activities, and therefore help in diagnosing the 
firm's competitive advantages. In other words it helps to understand the firm's issues 
involved with the promise of making customer value. 
 
On the other hand the value chain model was developed by Michael Porter and it was 
one of the most used methods in clusters assessment worldwide. The figure below 
shows the value-chain model. 
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 Figure 2.2 Value-Chain Model 
Source: porter (1998) 
The researcher had chosen twelve dimensions in order to assess the competitiveness 
of each company, where these are based on the value chain model and the diamond 
model, where they are illustrated below: 
The primary value chain activities are: 
1. Logistics/ Inbound: the distribution of manufacturing after the raw materials 
are received and warehoused. 
2. Operations: the transformation process of inputs into services and finish 
products. 
3. Logistics/ Outbound: The warehousing and distribution of the finished goods. 
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4. Marketing and sales: Placing the product on the market generating sales 
reaching the right people interested to buy it 
5. Service: The tool used to offer the product on the market and the service 
offered after the product is sold (customer service) 
This Primary Activities are supported by: 
6. The infrastructure of the firm: organisational structure, control system, 
company culture etc. 
7. Human resource management: employee recruiting, hiring, training, 
development and compensation. 
8. Technology development: technologies to support the value chain activity 
9. Procurement: purchasing input such as materials, supplies, and equipments. 
The other competitiveness dimensions of the company 
10.  Margin: the percentage of profits out of the total price. 
11. Support activities: like association support, consultation support, services 
12. Policy support: tax and investment incentives, legal support, government 
support services. 
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2.8 Research framework 
The research structure consists of three dimensions. 
. Dimension 1: assessment of current clustering situation, through: 
 Assessment of clustering relationships of each one of the companies, such as: 
o Geographic concentration. 
o Vertical relationships across the supply-chain. 
o Horizontal relationships between companies. 
o Resource sharing. 
 Assessment of cluster strategic resources, such as: 
o Human resources. 
o Abundant of low-cost raw materials. 
o  Firm's infrastructure. 
o The specific infrastructure with training institutions, research and 
development organizations, and capital providing organizations, etc. 
o And technology resources. 
 
. Dimension 2: Companies' competitiveness assessment through: 
 Assessment of competitive advantages, and competitiveness of each one of the 
companies based on the 12 dimension competitiveness. 
 Assessment of the competitiveness of each company through financial analysis. 
 
Dimension 3: Effects of clustering on companies' competitiveness. 
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3. Methodology 
3.1 Introduction 
Research methodology according to Polit and Beck (2006) could be explained as:  
―techniques used to structure a study and to gather and analyse information in a 
systematic fashion‖. The research methodology for this thesis followed the logical 
procedure that is suggested by (Yin, 2009), which is: plan, design, prepare, collect, 
analyse and share. 
The carefully analysed and chosen research methods and techniques are described in 
the sections below, including the rationale behind the chosen research approach. 
Additionally, the chosen data collection methods, and analysis methods are also 
characterized. 
3.2 Research purpose 
This thesis will go through different stages of research. The thesis will first describe the 
area of research which is the Palestinian pharmaceutical companies; In order to create 
a general understanding of this area, the study then will try to make generalizations 
from the data collected and draw a picture of the current situation of the companies. 
Such things make this study apply to the basis for the descriptive research (Yin, 2003). 
The research will also be exploratory in its methods as it seeks to explore what is 
happening, and to ask questions about it. This will be useful when not enough is known 
about a phenomenon (Gray, 2013). The thesis will also try to explain the different 
reasons or underlying causes for the observed events, which is synonymous with 
explanatory research (Gray, 2013). 
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This research has started with the available literature on the cluster, and 
competitiveness' concepts, the main reason for this process is to deeply understand the 
context of the research and to highlight on previous literature that will help the 
researcher to adapt the model that will be used in this research.  
After building up the model and identifying the indicators which are demonstrated in the 
previous chapter, the research measures and analyses the current situation, and 
measures the indicators that have been specified in the literature. The main objective of 
this research is to investigate the extent of clustering on companies‘ competitiveness. 
The researcher uses different methods in order to answer the research questions, which 
will be using a questionnaire, making interviews, documentary analysis, and on-site 
visits and observation. 
 
3.3 Exploring the available methodologies 
The research explores some research alternative methodologies, these methodologies 
according to Saunders et al. (2009), Goodman & Kruger (1988),  Bell (1999), and (Gray, 
2013) are:  
o Experiment research 
It ―attempts to provide a blue print that enables the researcher to structure a 
research problem in such a way that the outcome is the production of valid, 
objective and replicable answers‖ adapted form Hill (2004), and from Gill & Johnson 
(1997) which consists of four basic steps: 
1. Delineate the research question or problem 
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2. Identify the factors that explain or cause variation in the dependent variable. 
3. Operationalize the dependent and independent variables 
4. Neutralise the effects upon the dependent variable. 
 
o Analytical surveys 
This is the most popular and common methodology and most frequently used, it 
allows you to collect quantitative data which often can be obtained by (Saunders et 
al., 2009): 
1. A questionnaire that admitted to a sample 
2. Structured observation associated with organisation and methods (O&M) 
research. 
3. Structured interviews, where standardised questions are asked for all 
interviewees 
4. Observation technique   
o Case study 
Case study could be qualitative which leads to detailed descriptions of specific 
situations using interviews, observations, document review, or it could be 
quantitative which gives a numerical description such as frequency, and average, 
etc. (Guest et al., 2013).  
o Histories  
The use of administrative records and documents as a primary source of data 
(Bryman, 1989), this research method have three broad stages (Goodman & 
Kruger, 1988): 
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1. Formulate research question 
2. Examine evidence 
3. Compare evidence and research question 
o Action Research 
The action research strategy explicitly focuses on action, in particular promoting 
change within the organisation (Saunders et al., 2009). As described it is 
―essentially an on-spot procedure designed to deal with a concrete problem located 
in an inadequate situation. This means that ideally, the step-by-step process is 
consequently monitored over varying periods of time and by a variety of 
mechanisms (questionnaires, diaries, interview and case studies, for example) so 
that the ensuing feedback may be translated into modifications, adjustments, 
directional changes, redefinitions, as necessary so as to bring about lasting benefit 
to the on-going process itself rather than to some future occasion‖ (Cohen & 
Manion, 1994) . 
 
o Narrative inquiry 
According to Hill (2004) Narrative inquiry involves the collection and development of 
stories, either as a form of data collection or as a means of structuring a research 
project. Informants often speak in a story form during the interviews, as the 
researcher, listens and attempts to understand their stories. 
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3.4  Selecting the most appropriate methodology 
As already stated in the literature review, and since this research is a descriptive 
research, the researcher adopted a case study method in the research in order to be 
able to describe the characteristics of the current situation of the companies. The study 
can involve single or multiple methods, and numerous levels of analysis (Creswell, 
2012). The case study may combine more than one data collection method such as 
interviews, observation, documentary analysis and questionnaires, which allows using 
multiple sources of data (Saunders et al., 2009). Such thing is called triangulation, 
which is collecting of data over different times or from different sources, which will help 
answering the different research questions, and to balance out any of the potential 
weaknesses in each data collection method (Gray, 2013). 
3.5  Exploring the available data collection methods 
The data collection methods could be classified according to the nature of the 
collected data and to the method that was used into three types: quantitative, 
qualitative, and a mixed method. Brief descriptions of each of them are in the 
following section. 
o Quantitative  
Many definitions of quantitative research are actually exists. However most of them 
are defining quantitative research as numerical representation and manipulation of 
observations for the purpose of describing and explaining the phenomena that 
those observations reflect (Sukamolson, n.d.). Creswell (1994) has defined the 
quantitative research as a type of research that is "explaining phenomena by 
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collecting numerical data that are analysed using mathematically based methods (in 
particular statistics)". 
Sukamolson (n.d.) illustrated that because of the nature of the quantitative research 
which depends on numerical data, it seems to answer particular questions that 
looks like, how many ... ?, what is the percentage of … ?, and on average is there a 
significance difference between ... ?, etc.. Note that all of these questions need to 
be answered quantitatively. 
Sukamolson (n.d.) also indicated that there are several types of quantitative 
research. And it could be classified as 1) survey research, 2) correlational research, 
3) experimental research and 4) causal-comparative research. Anyway, none of 
these types are applicable to our study. 
 
o Qualitative  
Qualitative research has been defined in a variety of ways. In one definition, 
Strauss and Corbin (1998) identified qualitative research as: "Any type of research 
that produces findings not arrived at by statistical procedures or other means of 
quantification. It "qualitative research" can refer to research about persons' lives, 
lived experiences, behaviours, emotions, and feelings as well as about 
organizational functioning, social movements, cultural phenomena, and interactions 
between nations." 
Strauss and Corbin (1998) also illustrated that it is the best to use qualitative 
research when the methods are: (a) complementary to the preferences and 
personal experiences of the researcher, (b) congruent with the nature of the 
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research problem, and (c) employed to explore areas about which little is known. In 
addition to the reasons mentioned above, Miles and Huberman (1994) indicated 
that qualitative research is conducted to: (a) confirm previous research on a topic, 
(b) provide more in-depth detail about something that is already known, (c) gain a 
new perspective or a new way of viewing something, and (d) expand the scope of 
an existing study. Based on this collection of reasons, qualitative methods were 
appropriate for this study. 
 
o Mixed Method  
This method uses quantitative and qualitative data collection techniques and 
analysis procedures, either at the same time or one after the other but not combine 
them (Saunders et al., 2009).   
 
3.6  Selection the most appropriate data collection method(s) 
Through reviewing the above literature, it is clear that the selection of the research 
method that should be used in order to accomplish the research objectives is not an 
arbitrary decision, and don't depend on the researcher's mind to decide what he 
wants to do. On the contrary it should be done after a carefully investigation of the 
research nature, research context, research questions, and how the answers of the 
research it would be. 
This research as stated earlier is a descriptive research, which means it tries to 
describe the current situation of the pharmaceutical industry in Palestine, and give a 
clear picture on it, which is a qualitative issue and couldn‘t be answered just by 
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numbers. On the other hand, the research context is just four companies, which is 
considered to be small to apply quantitative methods, and quantitative analysis. 
Finally, and the most important is the research questions, which are asking about 
qualitative answers, such as, To what extent does …?, and how? questions which 
needs to have a qualitative answers. Nevertheless, the researcher used the case 
study research method, which enables the use of triangulation strategy, which as 
stated before, refers for using multiple sources of data by using different techniques 
(Saunders et al., 2009). 
The multiple methods provide better opportunities to answer the research questions 
and allow to better evaluating the extent to which research findings can be trusted 
and inferences made from them (Tashakkori & Teddlie, 2003). 
 
A qualitative research may use several data collection methods (Gill & Johnson, 1997), 
(Hill, 2004), (Bell, 1999). The following shows the five methods that had been used in 
this study, where usually two or more approaches could be used as a part of the 
investigation (Hill, 2004):  
Table 3.1: methods for data collection 
Method Description 
Structured interviews, also 
known as a standardized 
interview or a researcher-
Fixed format interview in which all questions 
are prepared beforehand and are put in the 
same order to each interviewee. In this case, 
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administered survey the data is collected by an interviewer rather 
than through a self-administered 
questionnaire. It could be quantitative or 
qualitative research methodology. 
Unstructured interviews Interviews are undertaken in an informal style 
in that respondents are allowed considerable 
latitude in the aspects addressed in the 
discussion. There may even not be a pre-
determined set of questions or aspects to be 
systematically discussed during an interview. 
Semi-Structured interviews Unlike the last method, semi-structured 
interviews comprise more specific and 
precisely formulated questions around which 
discussion is built. 
Observation The researcher observes relevant activities 
within an organisation in either a structured or 
unstructured format. 
Archival information 
analysis 
This method concerns the systematic 
analysis of existing materials. Typically, this 
constitutes prime data that are records of 
transactions and activities together with 
contemporary and historical controls and 
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measures of performance per se or derived 
from source data. 
Note: Taken from (Hill, 2004) 
3.7 Research Population 
The Palestinian pharmaceutical companies that exist in the West Bank are Birzeit 
pharmaceutical company, Jerusalem pharmaceutical company, Dar Al-Shifa'a for the 
Manufacturing of Pharmaceuticals (PHARMACARE), and the Chemical Jordanian 
Factory Company. These four companies represent the context of the study. Since the 
population is small; the researcher had conducted all of it, and no sampling techniques 
were utilized. 
 
3.8 Data collection  
Qualitative research can be conducted by utilizing a variety of data collection techniques 
or by choosing one technique in particular. Marshall and Rossman (1999) suggested 
that data collection methods in qualitative research could be categorized into four 
categories: (a) participation in the setting, (b) direct observation, (c) in-depth interviews, 
and (d) document analysis. According to Yin (1994), there is ―no single source has a 
complete advantage over all the others. In fact, the various sources are highly 
complementary, and a good case study will therefore want to use as many sources as 
possible‖. 
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The researcher used different data collection methods in-order to provide the majority of 
data. The methods were structured, semi-structured, and unstructured, also the 
Triangulation strategy were used. The main used methods are 
 Interviews: The researcher had utilized in-depth, individual face to face interviews as 
a primary method of qualitative data collection, and had made a criteria to select the 
participants in the interviews in order to achieve the best results of the study and 
enhance its trustworthiness, such criteria are: 
 Working in the management, to be in contact with most of the details related 
to the industrial process. 
 Have a sufficient work experience in his position in the company,   
 Easily available, so can reach him when it is needed for the study. 
Such criteria was mostly applicable to the production managers of each company, who 
were in touch with the whole processes of the industry, from planning of the products, 
until it reaches the market, the higher level of management was excluded from the 
interviews because of its difficulty to be reached and have their time. 
In order to have the willingness of the interviewees to participate in the interviews, the 
researcher had contacted them through different ways such as social relations, 
friendships, or through referring of the pharmaceutical industries inspector of the 
ministry of health. The interviews were held between 25 November to 10 December 
2014, where they were held on site in closed offices, where there is no interruption, and 
it lasts between 1.5 to 2.5 hours. 
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The interviews' questions were designed in structured, semi-structured, and 
unstructured ways, where these questions have been adopted from an existing study 
that was developed by the Palestine cluster project which was executed by the 
"Palestinian Federation of Chambers of Commerce, Industry, and Agriculture". The 
interviews have been divided into two sections as follow: 
1- Structured: where this part have been designed in order to measure the 
dependent variable according to the theoretical framework, which is the 
competitiveness of the companies. Where it includes 12 Pillars which were 
illustrated in the previous chapter which are; Firm Infrastructure, HR 
Management, Technology Development, Procurement, Inbound Logistics, 
Operations, Outbound Logistics, Marketing and Sales, Service, Margin, Support 
Activities, and Policy Support, and it was ranked numerically in order to enable 
comparison between companies in each value chain activity.  See (appendix 1). 
2- Unstructured, and semi-structured: this part had been designed in order to 
measure the independent variable according to the theoretical framework, which 
is the clustering of the pharmaceutical industry. Where the questions have been 
designed to measure the strategic resources such as knowledge, and 
technology, infrastructure, and the clustering relationships, such as the 
geographic location, vertical and horizontal links, and any collaborative projects 
had been undertaken. 
And the interviews' questions had also concentrated on some general information 
about the needs for change, cost of raw material, future plans, barriers facing 
competitiveness, accessing new markets, and understanding clustering, in order 
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to answer the question of the possibility of forming cluster of the pharmaceutical 
industry. To see questions, see (Appendix 2). Finally, an interview protocol was 
utilized during the interviews.   
 Site visit and observation: The researcher had made an on-site visit to each one of 
the companies, and evaluated the actual situation of the companies' different 
sections and departments such as the operation, warehouse, laps, sales, 
procurement, etc. to be more aware and familiar with industry to answer some of the 
questions that could be answered by observation. 
 Document Analysis: Document analysis refers to the documents, whether public or 
private records, about the participants in a research study (Creswell, 2012). The 
retrieved documents used in this study were the pharmaceutical companies' profiles, 
financial disclosures, Palestinian Central Bureau of Statistics reports, etc. The 
documents were reviewed as a means of gaining additional insight into the 
economical and financial situation of the pharmaceutical companies, to help in 
analysing the competitiveness of the companies. 
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3.9 Data Analysis  
Data analysis has two purposes: (a) to understand the participants‘ perspectives, (b) 
and to answer the research questions. Marshall and Rossman (1999) defined qualitative 
analysis in terms of organizing and attributing meaning to the data. To accomplish these 
tasks, I followed the three-phase procedure described by Miles and Huberman (1994) 
which includes: (a) data reduction, (b) data display, and (c) conclusion drawing and 
verification. 
Data Reduction 
Data reduction is the first phase of qualitative data analysis (Miles & Huberman, 1994). 
Data reduction involved the process of selecting, simplifying, and extracting themes and 
patterns from written field notes, transcripts, and other available resources. To 
accomplish this task, I read and re-read interview transcripts while searching for 
similarities and differences in themes. Then I assigned code names to those themes 
that were detected and then organized into categories of related topics, patterns, 
concepts, and ideas that are gain from the interviews. 
Data Display 
Identified by Miles and Huberman (1994) as the second phase of data analysis, data 
displays are tools for presenting the results of the data reduction. Displays are used to 
convert information into an accessible summary to facilitate later conclusion drawing. 
Display techniques include matrices and networks. Matrices are rows and columns of 
data that have been extracted from coded transcripts and are organized according to 
themes. Networks are charts that summarize information by providing a picture of 
reduced data, as it exists within the context of the collected data. 
72 
 
According to Miles and Huberman (1994), a particular technique must be dictated by the 
research questions and the related concepts. Once the appropriate technique was 
identified, data displays were created within each case or for each individual, as well as 
across each case, to demonstrate findings across all available sources of information. 
Conclusion Drawing and Verification 
The final phase of data analysis, according to Miles and Huberman (1994), consists of 
drawing initial conclusions based on cross-case data displays and then subjecting these 
initial conclusions to verification procedures. These procedures are intended to verify 
that findings are appropriate before they are labelled as conclusive results. In qualitative 
research, results are verified and considered appropriate by evaluating their 
trustworthiness. The following section is dedicated to discussing the establishment of 
trustworthiness of results. 
 
3.10 Trustworthiness 
While quantitative research relies on measures of reliability and validity to evaluate the 
utility of a study, qualitative research can be evaluated by its trustworthiness (Lincoln & 
Guba, 1985). The establishment of trustworthiness is necessary to confirm that the 
research outcomes are the truth and will enhance the professional practice (Holloway & 
Wheeler, 2010). The model of Lincoln and Guba (1985) was implemented to ensure 
validity and reliability. The model uses four constructs credibility, transferability, 
dependability and conformability. A description of each of these concepts is included in 
the following paragraphs. 
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Credibility  
Credibility or truth–value in qualitative research asks how confident the researcher is 
with the truth of the findings based on the research design, methods, and the context in 
which the study was undertaken (Lincoln & Guba, 1985), which in other words 
corresponds to the concept of internal validity in quantitative research. The researcher 
relied on triangulation and referential adequacy to enhance credibility, which are 
described below.  
 Triangulation: Lincoln and Guba (1985) explain triangulation as ―the use of 
multiple methods to collect and interpret data about a phenomenon so as to 
converge on an accurate representation of reality‖. In this study data was 
collected by multiple methods; interview, survey, observation, and document 
analysis. 
 Referential adequacy: According to Lincoln and Guba (1985) the raw data 
collected must be adequate to allow ―later analysis and interpretations‖. In this 
study interviews was recorded and transcribed ensuring that the raw data can 
undergo further analysis and interpretation. 
 
Transferability 
 
Transferability or could be known as applicability is similar to the concept of external 
validity in quantitative studies, transferability seeks to determine if the results relate to 
other contexts and can be transferred to other contexts (Lincoln & Guba, 1985), Steps 
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taken to ensure transferability include thick description and purposive sampling (Lincoln 
& Guba, 1985).  
 
 Thick description: refers to a rich, thorough description of the research setting, 
and the transactions and processes observed during the inquiry (Miles & 
Huberman, 1994). In this study the researcher presented a thick description of 
the setting, participants involved in the study, method of data collection and 
methodology. 
 Purposive sampling: According to Miles and Huberman (1994), this requires ―a 
non-probability sampling method in which the researcher selects participants 
based on personal judgment about who will be most informative‖. 
 
 
Dependability 
Similar to the concept of reliability in quantitative research, dependability refers to 
whether or not the results of the study are consistent over time and across researchers 
(Lincoln & Guba, 1985; Miles & Huberman, 1994). To address dependability in this 
study, the researcher relied on a peer examination which was suggested by Lincoln and 
Guba (1985) and he made use of expert supervisors to reinforce dependability of the 
study. 
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Confirmability  
 
Confirmability or neutrality assumes that the findings are reflective of the participants‘ 
perspectives as evidenced in the data, rather than being a reflection of the researcher 
perceptions or bias. In this study to avoid bias, the researcher audited the research 
process under supervision of the research supervisor. 
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CHAPTER FOUR 
 
4.1 Results and discussion 
4.2 Interviews Results 
4.3 Survey Results 
4.4  Financial analyses 
4.5  The answers of the research question. 
4.6 Cluster map  
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4. 1 Results and discussion 
 
The results from the structured and unstructured interviews, observation, and 
documents are provided and analysed in this chapter. The first section presents the 
unstructured interviews results which illustrates the clustering situation of each 
company, and the whole industry, according to the first dimension of the research 
structure mentioned in chapter two, then the second section displays the survey results 
"structured interviews", which were designed in order to measure the competitive 
advantages of each company, and to get and overall view on the competitiveness of 
each company as in dimension two, finally the third section displays financial analysis of 
each company to compare with the results gained from the structured interviews. 
 
4.2 Interviews Results 
The interviews have been done with the operation and professional manager in every 
one of the four pharmaceutical firms, because of the difficulty in meeting the higher level 
of management. The interviews were hold in the manager's offices, and it took the 
shape of semi-structured and unstructured format. The time of the interview was 
between 60-150 minutes. 
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The questions and answers of the interviews are as follow:  
Q1. Why did you establish your business in this area? 
The respondents –interviewees- demonstrated that their factories were started in these 
areas since the beginning of their manufacturers, when they were just a simple labs, in 
other words they didn‘t change their locations from city to another one. Most of them 
said that they were supposed to work in Jerusalem – the capital of Palestine -, but due 
to the political situation in the West Bank because of the Israeli occupation it was 
difficult to work in Jerusalem, thus Ramallah was the best option to start this business 
in. On the other hand most of the beginners in the pharmaceutical industry in Palestine 
were Christians, where Ramallah and Bethlehem were the concourse of the Christians. 
So they were started in these areas. And according to Pharmacare which is the newest 
one among the other manufacturers, it was established in Ramallah to be in the middle 
of the West Bank, therefore the main reason for selecting the location of the 
manufacturers was its closeness from the residence area of its founders. 
 
Q2.What are the specific benefits of being located where you are? 
The interviewees that exists in Ramallah said that their place is a strategic place, 
because it is in the middle of the West-Bank (their Main Market ) , and it is also relatively  
stable city among others, attracts most of the Business Development Services (BDSs), 
closeness to the decision making people, and it is also have one of the best 
infrastructure compared with other cities. 
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For BJP most of the benefits apply, however, it is gain more advantages for the southern 
cities. 
 
Q3.What disadvantages do you face because of your location? 
They said that there is no disadvantage for the place, because they considered the  
West Bank as a small area so that they can reach everywhere easily, and they have the 
infrastructure that the industry needs. 
 
Q4.What links do you have with other businesses in your sector? 
They considered that most of the relationships with the other competitors are limited, 
since there is an aggressive competition between manufacturers, on the other hand 
they have a good links with other related industries, such as printing, packaging, 
transportation, IT developers, etc. However, Birzeit Company had owned the company 
of Palestine for printing and publication, and they work with Al-Barq company for 
transportation of medicines, while they have no exclusive distributer, and have a direct 
contact with the customers, on the other hand JPC had become a partner with Ugarit in 
"Dar Al-Qalam" printing company, and all the companies have a relationships with 
plastic manufacturers, in order to get containers of the medicines, while Birzeit has a 
machine for tablet plastics in its manufacturer which is the only manufacturer that have 
such machine. However, for the sake of lobbing there are few organizations that put 
them under the same ceiling. Such as, Chamber of commerce, and the union of 
pharmaceutical industries. 
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There is also some links with IT companies, such that BPC work with Bisan company to 
develop their inventory control and marketing control. 
On the other hand BJPC work with Sukhtian company as their exclusive distributer to 
the local market where they sell about 87% of their total sales locally and 13% are 
exported. 
 
Q5.Do you have links with the Universities or R&D facilities in the governorate? 
Most of them said that they offer practical training opportunities for many Universities 
students in many fields such as engineering, pharmacy, and physics. 
For a long time Birzeit university was testing the medicines sold to MOH in its 
laboratories as a third party between the company and the ministry of health. Currently 
In Al-Najah University there is a plan to build a Biowaver ―clinical testing‖ unit. Where all 
the companies need clinical testing for the medicine to be able to register it in the 
ministry, and get the licenses needed to produce it commercially, where currently they 
test their products in Jordan, with an average cost for each test of 30,000 USD. For 
example just BPC makes 50 tests yearly, that is about 1,500,000 USD. On the other 
hand BJPC covers some of the travelling expenses of pharmacy, and medicine students 
to take training courses in other countries, and this is done in a collaborative way with 
the universities,  
JPC is a partner with Palestine Polytechnic University, "the biotechnology center" in a 
project of a business incubator for the students of biotechnology unit funded by the 
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world bank. And some of the biotechnology master degree students are working in the 
JPC. 
 Finally, the researcher found that there is no real R&D activities shared between the 
manufacturers, and the universities. On the other hand there is no private or even public 
R&D center which work for  producing new formulas, or even for testing medicines. 
The production manager of Birzeit company said that we can't work with the universities 
if they follow us, but if they took a step forward and produced the formulas, and tested it 
and even registered it we sure can buy it from them, this save so much time for us and 
makes money for the universities and the manufacturers. 
 
Q6.What do you consider to be your main competitive advantage?  
Most of them answered we have the advantages of  
-Wide variety of products, quick response system for new order. 
-Quality: functionality, shape, color, dose, etc 
-Price less 30% of foreign medicines. 
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Q7.What are your major problems and barriers to………….? 
•Increasing your competitiveness? 
•Access more markets? 
All of the interviewees agreed that the Palestinian market is a saturated one but there is 
an opportunity to enter new markets and make new medicines. However, this needs 
more capital. 
Some markets to invest in needs to build firms there in order to be able to sell in these 
markets, like Algeria. Where BPC, and JPC, have firms there. JPC had also a complete 
firm work in Jordan, while Pharmacare bought a 10% of the Iraqi pharmaceutical 
manufacturer to enter the Iraqi market which is considered as a promising one, and they 
established Pharmacare premium in Malta, to be able to enter the euro market because 
many countries want to visit the manufacturer before give him the license to export, and 
this is hard due to the political situation,  
Another so important factor is the Israeli occupation, which controls the boarders and 
makes it hard to get the required raw materials at the time they need it, and put many 
limitations on exportation. Therefore it makes the general economic situation in the 
Palestinian territories to be instable one.   
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Q8.If you could make three major changes to your business what would they be? 
They gave common answers which are: 
 Establish a research center.  
 New production lines. 
 The best solution is commercial collectivity in the Arab countries to be able to 
sell there without limitations. 
 
Q9. Do you have any investment plans for the next 12 months? 
Most said yes, investing in new lines, registering new products, testing the stability of 
new products, where this is done in Jordan. some said that they invest now in Algeria 
market, because it is new market and many companies are targeting it. Others like 
Pharmacare are working on their firm in Malta,  
 
Q10. How do you see your competitors in the next 5 years?  
All of the interviewees answered that they see their competitors are expanding, in both 
the local and the outside markets through producing new products, entering more 
markets, such as: Jordan, Algeria, Iraq, Belarus, Russia , Uzbekistan, Pakistan, 
Armenia, Kazakhstan, Europe and ……etc.  
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Q11. Who are your main customers and markets? 
they sell to the MOH, local UN office, private pharmacies, and drug stores. 
Birzeit and Pharmacare said 75% of the their production is sold in the Local market 
while 25% is exported to Algeria, Jordan, Bella Russia ; Uzbekistan, Pakistan, Armenia, 
Kazakhstan, etc. While Pharmacare demonstrated that its exportation which is 25% of 
its production is divided as  11% to Bella Russia, and 14% to Europe. BJPC  is the only 
one with lower percentage of production which is going for exportation which is 13% of 
the total production. 
 
Q12.Who are your main competitors? 
They see that their competitors are the Israeli Companies, and the imported products 
from USA, Europe, which takes more than 45% of the local market, and of course the 
local competitors; which are the four manufacturers. 
   
Q13.What is the percentage of the total cost that is made up by the raw materials 
and components? 
The raw materials only makes 15-20% of the total cost, Most of the cost goes for power, 
such as electricity, and fuel which is used for air conditioning and ventilation, and there 
is a much cost for supporting and logistic operations, And not to forget the Testing and 
R&D cost which is basically for developing new formulas. 
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Q14.What do you understand about the Clustering? 
They mostly understand that clustering is a collaboration effort which aims to increase 
their competitiveness through innovation, and lowering production costs. 
Q15.What Benefits do you think that the clustering will bring for your business? 
1- Competitiveness enhancement. 
2- Reduction of production costs. 
3- Increasing of profit margin. 
4- And development of production technologies.   
 
 
Q16. Currently, are you practicing any collaborative projects or assignments?  
The only collaborative practice that they have is a collaborative marketing to the Belarus 
markets, which is done through "Care" company. Care is a Belarus company for 
Palestinian pharmacists who live there, they buy drugs from all local manufacturers and 
sell it Belarus, Armenia, Uzbekistan, and other eastern Europe countries. There is also 
an experience done in the beginning of 2001 where the firms agreed on the allocation of 
several products, 30 for each plant so that no other firm produce these types, and this 
raise the efficiency and lowered the cost of production, but this stopped because the 
administration found that some types have sold more than others, and there is also an 
experience of merger between BPC, and JPC, but it also failed before being a truth. 
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On the other hand they said we can't buy together because of the complexity of the 
process of procurement, for example BPC buy about 2000 raw material, and it is not 
easy to buy them with others. On the other hand the director of union of pharmaceutical 
industries said that every raw material comes to every firm has a license for just this 
firm, and can't be used with others. 
To know more about this issue the researcher had asked the production manager of pro 
company for Veterinary medicines in Hebron, and he said we work on the same 
principles of human medicines, as in all over the world there is just four 
pharmacopoeias, and we all work on them.  But we can't buy from another 
manufacturer, because there is some active materials we put in the formula, but we 
didn‘t put them in the ingredient paper to keep our secret, so if there is a local supplier 
we will work with him, but he must keep our secrets, and don‘t let other manufacturers 
to know what we bought. 
To understand the differences between companies in a better way the researcher had 
made the following comparison between companies in terms of clustering relationships 
of each company, where these comparisons have been summarized from the 
unstructured interviews results.  
Birzeit Company 
Relationship type Description   
Location  Ramallah Reasons Benefits 
 Center of the 
West Bank. 
 Middle of the 
West-Bank. 
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 Closeness to 
the residence of 
the founders. 
 Closeness to 
Jerusalem.  
 Stable city. 
 Attractiveness of 
the BDSs. 
 Closeness to the 
decision making 
people. 
Vertical 
relationships 
 Relations with plastic manufacturers, and the only one that 
have a plastic machine inside the manufacture. 
 Ownership of the company of (Palestine for printing and 
publication), 
 Contract Al Barq Transportation Company. 
 Have a contract with Bisan Company for IT development for 
inventory and marketing control. 
Universities & R&D 
relationships 
 Birzeit university was a testing center between MOH & BPC 
 The manufacturer is a training center for some of the 
university students. 
 Make clinical testing in Jordanian labs. 
 There is no real R&D between manufacturers and the 
universities. 
Collaborative 
projects 
 Just collaborative marketing to Belarus markets. 
 There is no any resource sharing efforts. 
Source: interview with Birzeit Company production manager. 
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Jerusalem Company 
Relationship type description   
Location  Ramallah Reasons Benefits 
 Center of the 
West Bank. 
 Closeness to 
the residence of 
the founders. 
 Closeness to 
Jerusalem.  
 middle of the 
West-Bank. 
 Stable city. 
 Attractiveness of 
the BDSs. 
 Closeness to the 
decision making 
people. 
Vertical 
relationships 
 Partner with Ugarit printing company. 
 Relations with plastic manufacturers. 
 Distribute medicines directly. 
Universities & R&D 
relationships 
 Partner with PPU biotechnology center in a project of 
business incubators. 
 Make clinical testing in Jordanian labs. 
 There is no real R&D between manufacturers and the 
universities. 
Collaborative 
projects 
 Just collaborative marketing to Belarus markets. 
 There is no any resource sharing efforts. 
Source: interview with Jerusalem Company production manager. 
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Pharmacare Company 
Relationship type description   
Location  Ramallah Reasons Benefits 
 Center of the 
West Bank. 
 Closeness to 
the residence of 
the founders. 
 Closeness to 
Jerusalem.  
 middle of the 
West-Bank. 
 Stable city. 
 Attractiveness of 
the BDSs. 
 closeness to the 
decision making 
people. 
Vertical 
relationships 
 No exclusive printing company. 
 Relations with plastic manufacturers. 
 Distribute medicines directly. 
Universities & R&D 
relationships 
 Make clinical testing in Jordanian labs. 
 There is no real R&D between manufacturers and the 
universities. 
Collaborative 
projects 
 Just collaborative marketing to Belarus markets. 
 There is no any resource sharing efforts. 
Source: interview with Pharmacare Company production manager. 
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Beit Jalla Company 
Relationship type description   
Location  Beit Lehem Reasons Benefits 
 Closeness to the 
residence of the 
founders. 
 Stable city. 
 Closeness to 
the southern 
areas. 
Vertical relationships  No exclusive printing company. 
 Relations with plastic manufacturers. 
 Distribute via Sukhtian company, have no direct 
distribution. 
Universities & R&D 
relationships 
 Covers travelling expenses of medicine students to get 
training courses in other countries. 
 Make clinical testing in Jordanian labs. 
 There is no real R&D between manufacturers and the 
universities. 
Collaborative projects  Just collaborative marketing to Belarus markets. 
 There is no any resource sharing efforts. 
Source: interview with Beit Jalla Company production manager. 
From the tables above, the researcher had found that Birzeit Company had the best 
cluster relationships through the vertical relationships, and universities R&D 
relationships, where it enjoys some contracts with supporting industries, such as plastic 
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manufacturers, transportation, and IT developing companies, and own complementary 
industries such as printing and publishing company. Whereas the other companies don‘t 
have such strategic relationships. 
On the other hand, Jerusalem, Pharmacare, and Birzeit companies have a good 
geographic location, due to its location in industrial zones in Ramallah, in the middle of 
the West Bank, and close to the decision makers, and business development services. 
While only Beit Jalla is in another city which is Beit Lehem in southern of the West 
Bank, and there is few collaborative actions between the companies that is marketing to 
Bella Ruse, where this is not done from the companies themselves, but from the 
marketing company in Bella Ruse. 
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4.3 Survey Results 
In this section the main characteristics and answers of the participants in the survey will 
be explored. All data will be disaggregated by the factory name.  
The below tables shows the firms competitive advantages score "out of 5" in different 
dimensions according to the survey questions, where the score 1 means "low", 2 means 
"low to medium", 3 means "medium", 4 means "medium to high, and 5 means "high". 
Table 4.1 shows the score of companies‘ overall competitiveness based on the 12 
dimensions of the survey results with the mean of each dimension. 
Table 4.1: Firms' overall competitive advantages Score. 
Firms' overall competitive advantages Score 
N Questions JPC BPC BJPC PLC M. M. % 
1 Firm Infrastructure  3.8 3.9 3.31 3.69 3.68 73.6 
2 HR Management   3.3 3.67 3 3.4 3.35 67 
3 Technology Development 3.25 3.5 2.75 3.25 3.19 63.8 
4 Procurement 2.83 3 2.83 2.67 2.84 56.8 
5 Inbound Logistics 3.8 4 3.67 3.83 3.83 76.6 
6 Operations 3.73 3.91 3.82 4 3.87 77.4 
7 Outbound Logistics 3.6 4 3.4 3.6 3.65 73.0 
8 Marketing + Sales 3 3.26 3.04 2.96 3.07 61.4 
9 Service 3.25 4 3.5 3.25 3.5 70 
10 Margin 2 2 2 2 2 40 
11 Support Activities 2.4 2.8 2.4 2.4 2.5 50 
12 Policy Support 2 1.8 2.2 2 2 40 
        
 Individual Company average score at all Dimensions  3.09 3.32 3.01 3.08 3.13 62.5 
 Individual Company average score at all Dimensions % 61.8 66.4 60.2 61.6 62.5  
Note: scale of 0-5, where 5 is the best 
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Through studying table 4.1 which summarizes the 12 dimensions of competitiveness of 
each company, the researcher found that all of the companies' scores are almost similar 
to each other; this is because all of the companies are considered to be big companies, 
and have a good percentage of the market share. But while comparing the companies 
to each other, it was clear that Birzeit Company has got the best score of 
competitiveness compared to the other companies; this was achieved because of its 
better results in infrastructure, HR management, inbound and outbound logistics, 
marketing and sales, services, procurement, and support activities. However, to have a 
better understanding, and a more clearer view on the situation of each company in each 
one of the 12 dimension, the following tables show the scores of each company in every 
dimension of the survey. 
Table 4.2 shows the score of companies‘ infrastructure competitiveness based on 12 
dimensions with the mean of each dimension. The score of the companies are very 
close to each other and reflect the similarity of the companies‘ situation. Jerusalem 
mean score was 3.8, Birzeit got 3.9, while Beit Jala scored 3.31, and Dar Al Shifa 3.69. 
The overall mean for all the companies for firm Infrastructure is 3.5 out 5 or 70% which 
considered to be above medium "good" according to the scores. 
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Table 4.2: Firm Infrastructure Score. 
Firm Infrastructure Score 
N Questions JPC BPC BJPC PLC M. M. % 
FI1 Adequacy of physical infrastructure  4 4 4 4 4 80.0 
FI2 Adequacy of ITC systems employed 4 4 4 4 4 80.0 
FI3 Adequacy of quality / H&S / CSR certificates 3 4 3 4 3.5 68.0 
FI4 Adequacy of trade association(s) membership 2 2 2 3 2.25 45.0 
FI5 Adequacy of strategic planning practices 3 4 3 4 3.5 68.0 
FI6 Adequacy of working capital 3 4 3 4 3.5 68.0 
FI7 Adequacy of cash flow planning practices 4 4 3 4 3.75 75.0 
FI8 Adequacy of access to banks and commercial credits 4 2 3 2 2.75 55.0 
FI9 Adequacy of knowledge of breakeven sales 4 4 3 3 3.5 68.0 
FI10 Adequacy of accounts receivable and payable situation 2 3 3 4 3 56.7 
FI11 Adequacy of quality management system 4 4 4 4 4 80.0 
FI12 Adequacy of knowledge of the cost of poor-quality products or 
service 
4 4 4 4 4 80.0 
FI13 Adequacy of governance by industry standards or regulation 3 4 4 4 3.75 73.3 
 Individual Company average score at this Dimension  3.8 3.9 3.31 3.69 3.68 73.5 
Note: scale of 0-5, where 5 is the best 
Through studying the table 4.2 results, which reveals the infrastructure strengths or 
weaknesses, which will affects in its turn the competitiveness of the industry, will see 
that the adequacy of trade associations membership got the minimum score 2.25 of 5, 
or 45%, this mean that the pharmaceutical industry suffers from the ineffectiveness of 
such associations, and don‘t benefit from their activities.  While the next infrastructure 
disadvantage is the inadequate access of banks and commercial credits.  On the other 
hand the industry enjoys an advantage in management systems, management 
knowledge, physical infrastructure, and IT systems. 
Another point is that the firms in Ramallah district; PLC, JPC, and BPC, have an overall 
infrastructure advantage – the scores are 3.69, 3.38, 3.62- better than BJPC which is 
located in Bet Jala and has a score of 3.31 out of 5.   
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Table 4.3 shows the six dimensions that reflect Human Resource Management at the 
companies, and the mean for each dimension. The mean of the score for the 
companies are as following, Jerusalem was 3.30, Birzeit 3.67, Beit Jala 3.00, and Dar Al 
Shifa 3.40. The overall mean for all the companies for HR Management is 3.35 out of 5. 
Table 4.3: HR Management Score. 
HR Management  Score 
N Questions JPC BPC BJPC PLC M. M.% 
HR1 
Adequacy of method for recruiting the right person for the right 
job 
3 4 3 2 3.00 56.7 
HR2 Do you have a stable labour force 4 4 3 3 3.50 68.0 
HR3 
Adequacy of appropriate and regular training provided to 
personnel 
3 4 3 4 3.50 68.0 
HR4 Adequacy of the structured payment system 4 4 3 3 3.50 68.0 
HR5 Adequacy of the disputes or grievance procedure 2 4 2 3 2.75 51.4 
HR6 
Adequacy of number of sufficiently skilled personnel needed to 
run the business 
2 2 3 2 2.25 42.9 
 Individual Company average score at this Dimension  3.4 3.67 3 3.3 3.35 67 
Note: scale of 0-5, where 5 is the best 
 
The human resources competency of the pharmaceutical industry is 3.35/5, or 67%. 
where the lowest competency comes from the high number of sufficiently skilled 
personnel needed to run the business, where this type of industries needs a special 
knowledge, training, and experience, which makes its hard to get new workers, and will 
be a big loss if loose such experiences from the work. While the companies enjoy a 
good stable labour force, training, and good payment systems. Another thing it is clear 
that the bigger companies, BPC, and JPC have better HR competency than PLC, and 
BJPC. 
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Table 4.4 shows the companies‘ score for Technology Development. In order to observe 
the technology development on the companies, eight aspects were looked at .and their 
means were calculated. Jerusalem mean score is 3.25, Birzeit got 3.50, while Beit Jala 
scored 2.75, and Dar Al Shifa 3.25. The overall mean for all the companies for firm 
Infrastructure is 3.09 out 5. 
Table 4.4: Technology Development Score. 
Technology Development 
N Questions JPC BPC BJPC PLC M. M.% 
TD1 Adequate and easy access to technology 3 4 3 3 3.25 63.3 
TD2 
Adequate to in house designers or product development 
engineers 
3 3 3 3 3.00 60.0 
TD3 Adequacy of understanding of intellectual  3 3 3 4 3.25 63.3 
TD4 
Level of introduction of new products or processes in the last 5 
years 
4 4 3 3 3.50 68.0 
TD5 Adequacy of firm level innovation  2 3 2 3 2.50 50.0 
TD6 
Level of pursuit of new systems, trends or technology to upgrade 
processes 
3 3 3 4 3.25 63.3 
TD7 Level of tracking industry innovation and trends  3 4 3 4 3.50 68.0 
TD8 
Level of capitalization on innovative / new technology 
opportunities 
3 3 2 2 2.50 50.0 
 Individual Company average score at this Dimension  3.25 3.5 2.75 3.25 3.19 63.8 
Note: scale of 0-5, where 5 is the best 
 
The above table shows that technology Development Score in the industry is 3.19 out of 
5, or 63.8%. Where they suffer from low Level of capitalization on innovative and new 
technology, and low level of firm's innovation, and lack of R&D. And enjoy a good 
advantage in producing new products which actually are totally generic products, and 
tracking industry innovation and trends.  In an overall the best is Birzeit, and the lowest 
is bet Jala. 
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Table 4.5 with six dimensions reflect Procurement Management at the companies, and 
the mean for each dimension. The mean of the score for the companies are as 
following, Jerusalem with 2.83, Birzeit 3.00, Beit Jala 2.83, and Dar Al Shifa 2.67. The 
overall mean for all the companies for Procurement Management is 2.83 out 5. 
Table 4.5: Procurement Score. 
Procurement 
N Questions JPC BPC BJPC PLC M. M.% 
P1 Length of lead time for procurement of equipment and spares 4 4 3 3 3.50 68.0 
P2 Length of lead time for procurement of raw materials 3 3 3 3 3.00 60.0 
P3 Geographical closeness of raw materials  3 3 3 3 3.00 60.0 
P4 The ease of changing suppliers ( 0 difficult 5 easy) 1 2 2 2 1.75 35.0 
P5 Level of use of raw materials which are unique or not offered by 
many others 
2 2 3 2 2.25 42.9 
P6 Level of use of sub-contractors. Specify what they provide 4 4 3 3 3.50 68.0 
 Individual Company average score at this Dimension  2.83 3.00 2.83 2.67 2.83 55.64 
Note: scale of 0-5, where 5 is the best 
 
The procurement competency was 55.64% for the industry.  Where this low competency 
comes from the difficulty of changing supplier, and the level of using unique raw 
materials which come from other countries, and every raw material have to get a special 
license in order to buy it, this also in addition to the difficulty in importing raw materials 
through the Israeli borders. On the other hand Birzeit Company got the highest score 
due to its high level of inventory capital, and biggest stores. 
Table 4.6 shows the companies‘ score for Inbound Logistics. In order to observe the 
Inbound Logistics operations on the companies, six aspects were looked at .and their 
means were calculated. Jerusalem mean score is 3.8, Birzeit got 4.00, while Beit Jala 
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scored 3.83, and Dar Al Shifa 3.71. The overall mean for all the companies for firm 
Infrastructure is 3.83 out of 5. 
Table 4.6: Inbound Logistics Score. 
Inbound Logistics 
N Questions JPC BPC BJPC PLC M. M.% 
IL1 
Adequacy of storage facilities for raw materials and finished 
goods 
4 4 4 4 4.00 76.7 
IL2 Adequacy of an inventory control system 4 4 4 4 4.00 80.0 
IL3 Adequacy of the area for quarantined goods and returns 
procedure 
4 4 4 4 4.00 80.0 
IL4 Adequacy of space for raw materials and materials handling 4 4 4 4 3.75 73.3 
IL5 Adequacy of the goods inwards inspection system 4 4 3 4 3.75 75.0 
IL6 Adequacy of performance on the number of days of inventory 
held (12 months, 6 months 3 months 6 weeks) 
3 4 3 3 3.25 65 
 Individual Company average score at this Dimension  3.8 4 3.67 3.8 3.83 76.6 
Note: scale of 0-5, where 5 is the best 
 
Table 4.6 shows that the industry has a good competitiveness in inbound logistics, 
where they have a good inventory control, adequate area for materials and finished 
goods storage, where it suffers from long time of holding the inventory due to the 
process of procurement, and manufacturing. All firms almost the same.   
Table 4.7 shows the score of the companies‘ operations based on 11 dimensions with 
the mean of each dimension. The score of the companies are very close to each other 
and reflect the similarity of the companies‘ situation. Jerusalem mean score is 3.73, 
Birzeit got 3.91, while Beit Jala scored 3.82, and Dar Al - Shifa 4.00. The overall mean 
for all the companies for firm Infrastructure is 3.86 out 5. 
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Table 4.7: Operations Score. 
Operations 
N Questions JPC BPC BJPC PLC M. M.% 
O1 Adequacy of current technology. (Dilapidated, old, serviceable) 3 4 3 4 3.50 68.0 
O2 Adequacy of operating capacity 3 3 4 4 3.50 68.6 
O3 Adequacy of operating efficiency 4 4 4 3 3.75 73.3 
O4 Adequacy of production / process planning 4 4 4 4 4.00 80.0 
O5 Adequacy of the materials requirements planning system 3 4 3 4 3.50 68.0 
O6 Adequacy of the computerized system for handling business 
processes 
4 3 4 4 3.75 72.0 
O7 Adequacy of quality checks and systems 4 4 4 4 4.00 80.0 
O8 Adequacy of appearance and housekeeping of premises 4 4 4 5 4.25 86.7 
O9 Adequacy of flow visibility with dedicated work stations 3 4 4 3 3.50 68.6 
O10 Adequacy of Just In Time or similar quick response system 4 4 3 4 3.75 72.0 
O11 Adequacy of Health and Safety system 5 5 5 5 5.00 100.0 
 Individual Company average score at this Dimension  3.73 3.91 3.82 4.00 3.86 76.1 
Note: scale of 0-5, where 5 is the best 
 
Table 4.7 shows that the industry has a high competency in operation process, a score 
of 76.1%. where the lowest competencies comes from low operating capacity, machine 
technologies, material requirements, planning systems, and flow visibility between work 
stations. Whereas they have a very good health and safety systems, quality checks 
systems, and production planning. 
Table 4.8 Outbound logistics score is shown in table 4.7. Jerusalem mean score is 3.4, 
Birzeit got 4, while Beit Jala scored 3.6, and Dar Al Shifa 3.4. The overall mean for all 
the companies for outbound logistics is 3.60 out 5. 
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Table 4.8: Outbound Logistics Score. 
Outbound Logistics 
 
N Questions JPC BPC BJPC PLC M. M.% 
OL1 Adequacy of storage facility for finished products 4 4 4 3 3.75 73.3 
OL2 Adequacy of system for order processing 4 4 4 3 3.50 68.6 
OL3 Adequacy of system for scheduling deliveries 4 4 3 4 3.75 73.3 
OL4 Adequacy of On Time Delivery (0 often late 5 always on time) 3 4 3 4 3.50 68.0 
OL5 Adequacy of delivery system 3 4 3 4 3.50 68.0 
 Individual Company average score at this Dimension  3.6 4 3.4 3.6 3.60 73.00 
Note: scale of 0-5, where 5 is the best 
 
According the table 4.8 of Outbound Logistics all the firms enjoys high competencies, of 
73.00% as overall score for the cluster where this is because every company has its 
own system for distribution, and due to the availability of pharmaceutical warehouse that 
exists in every city. However, Beit Jala Company depends on unique reseller which is 
Sukhtian to reach every place in the West Bank. But Birzeit enjoys the best because it 
has a complete department for selling and order processing, with direct contact up to 
the final customer.  
Table 4.9 With twenty three aspects reflect the companies‘ performance at marketing 
and sales. Jerusalem mean score is 3.0, Birzeit got 3.26, while Beit Jala scored 3.04, 
and Dar Al Shifa 2.96. The overall mean for all the companies for outbound logistics is 
3.07 out 5. 
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Table 4.9: Marketing & Sales Score. 
Marketing + Sales 
 
N Questions JPC BPC BJPC PLC M. M.% 
MS1* Do you receive orders from sub-contracting (High is 0 Low is 5) 3 3 2 4 3.00 60.0 
MS2 Adequacy of a good spread of customers/clients 4 4 3 3 3.50 70.0 
MS3** Is there a significant change in your market? 3 3 4 3 3.25 65.0 
MS4*** 
Is there pressure from customers to make changes (5 For low  
pressure, 0 High pressure) 
4 4 4 4 4.00 80.0 
MS5 Adequacy of strategic partner 2 2 1 3 2.00 40.0 
MS6 Adequacy of market research undertaken 2 3 4 2 2.75 55.0 
MS7 Adequacy of identification of target customers and consumers 3 4 3 2 3.00 60.0 
MS8 Level of selling of niche products 3 3 2 2 2.50 50.0 
MS9 Geographical closeness of markets 4 4 3 4 3.75 75.0 
MS10 Adequacy of analysis of competitors and other market players 3 4 3 3 3.25 63.3 
MS11 Adequacy of monitoring changing consumer behaviour 2 3 3 3 2.75 54.3 
MS12 Adequacy of the branding policy 3 3 3 3 3.00 60.0 
MS13 Adequacy of catalogues, leaflets and other printed materials 4 4 4 4 4.00 80.0 
MS14 Adequacy of channels used for advertising 2 1 2 1 1.50 30.0 
MS15 Adequacy of trade fair attendance 3 3 2 2 2.50 50.0 
MS16 Adequacy of company web site / web presence 2 3 4 3 3.00 60.0 
MS17 
Adequacy of knowledge of potential importing countries' 
standards, customs and packaging requirements 
4 4 3 4 3.75 75.0 
MS18 Adequacy of sales target setting 3 4 3 3 3.25 63.3 
MS19 
Level of company's perception of the quality of their 
product(s) / service(s) compared to those of competitors 
4 4 4 4 4.00 80.0 
MS20 
Adequacy of packaging labelling and information (e.g. 
indicating ingredients, etc) 
4 4 4 4 4.00 80.0 
MS21 
Level of sales to end users/consumers (as opposed to 
intermediate customers such as distributors, wholesalers, 
agents, etc) 
3 4 3 3 3.25 63.3 
MS22 Is there an adequate marketing plan 3 3 4 3 3.25 65.0 
MS23 Adequacy and monitoring of channels of distribution 3 4 3 3 3.25 63.3 
 Individual Company average score at this Dimension  3.00 3.26 3.04 2.96 3.07 61.4 
Note: scale of 0-5, where 5 is the best 
*. Since the buyer's pressure is considered a disadvantage to the company, and when 
working with subcontractors, there will be a high buyer's pressure, rather than having a 
direct contact with the customers which decrease this pressure.  
**. If there is more significant change "growth" in the market, then this is the best 
situation. 
102 
 
***. If there is a high pressure from customers on the firm to make changes, then this is 
considered a disadvantage for the firm, while the best situation is when there is no 
pressure from customers on the firm to make changes on its products. 
 
 
According to the table 4.9 the overall score competency level is 61.4% in marketing and 
sales, that is due to the absence of strategic partners, low levels of market research, 
low level of niche products due to low R&D, low channels of advertising, low sharing in 
trade fairs,  while they have a good competence of knowing the regulations of other 
countries for exporting, good packing and labelling, catalogues, and brochures, a good 
but not so high branding policy, marketing plans, setting target market, etc.  
Table 4.10 shows the companies‘ score for service the companies provide for their 
customers. In order to observe the service, four aspects were looked at .and their 
means were calculated. Jerusalem mean score is 3.25, Birzeit got 4, while Beit Jala 
scored 3.50, and Dar Al Shifa 3.25. The overall mean for all the companies for firm 
Infrastructure is 3.5 out 5. 
Table 4.10: Service Score. 
Service 
N Questions JPC BPC BJPC PLC M. M.% 
S1 Adequacy of after-sales service 4 4 3 4 3.75 75.0 
S2 Adequacy of customer / consumer training in product  3 4 4 3 3.50 70.0 
S3 Adequacy of product / service set up operations  3 4 3 2 3.00 60.0 
S4 Adequacy of company product / service guarantee 3 4 4 4 3.75 75.0 
 Individual Company average score at this Dimension  3.25 4 3.5 3.25 3.50 70.0 
Note: scale of 0-5, where 5 is the best 
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Table 4.10 shows that pharmaceutical industry service competency is 70% which is 
high, where it is high in after sale services, and monitoring, where they have a quick 
response to the claims of customers. And they not provide product setup facilities, 
where the customers "pharmacies" have to do so. 
Table 4.11 shows the companies‘ score for Margin. Jerusalem score is 2.0, Birzeit 2.0, 
while Beit Jala scored 2.0, and Dar Al Shifa 2.0. The overall mean for all the companies 
for firm Infrastructure is 2 out of 5. 
Table 4.11: Margin Score. 
Margin 
 
N Questions JPC BPC BJPC PLC M. M.% 
M1 
What is the company's net margin? score (1=0-20, 2=21-40, 
3=41-60, 4=61-80, 5=81-100) 
2 2 2 2 2 40 
 Individual Company average score at this Dimension  2 2 2 2 2 40 
Note: scale of 0-5, where 5 is the best 
 
According to 4.11 the margin competence is 40%, because all the products are generic, 
and they aim to be price competence compared to the Israeli, and foreign competitors. 
And this is not a low competency because it provides price competitiveness to the 
industry. 
Table 4.12 Support Activities score is shown in table 4.11. Jerusalem mean score is 2.2, 
Birzeit got 2.8, while Beit Jala scored 2.4, and Dar Al Shifa 2.4. The overall mean for all 
the companies for outbound logistics is 2.45 out 5. 
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Table 4.12: Support Activities Score. 
Support Activities 
N Questions JPC BPC BJPC PLC M. M.% 
SA1 Adequacy of trade association support services / activities 2 2 2 3 2.00 40.0 
SA2 Adequacy of government support services / activities 2 3 1 1 1.75 35.0 
SA3 Adequacy of suppliers' support services / activities 3 4 3 3 3.25 65.0 
SA4 Adequacy of consultants' support services / activities 3 3 3 3 3.00 60.0 
SA5 Adequacy of agencies' support services / activities 2 2 3 2 2.25 45.0 
 Individual Company average score at this Dimension  2.4 2.8 2.4 2.4 2.5 50.0 
Note: scale of 0-5, where 5 is the best 
 
According to table 4.12 the pharmaceutical industry support activities 
competency is low 50%, where there is an inadequate government support, low trade 
associations support, low agencies support, with a good supplier's support.  
Last table 4.13 shows the score for policy support from the companies point of view 
based on 5 dimensions with the mean of each dimension. The score of the companies 
are very close to each other and reflect the similarity of the companies‘ point of view. 
Jerusalem mean score is 2, Birzeit got 1.8, while Beit Jala scored 2.2, and Dar Al Shifa 
2.0. The overall mean for all the companies for firm Infrastructure is 2.0 out 5. 
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Table 4.13: Policy Support Score. 
Policy Support 
N Questions JPC BPC BJPC PLC M. M.% 
PS1 Adequacy of preferential trade agreements for the sector 3 3 4 3 3.25 65.0 
PS2 Adequacy of inward investment incentives 1 1 1 2 1.25 25.0 
PS3 Adequacy of tax incentives 1 1 2 1 1.25 25.0 
PS4 Adequacy of the legal system to support enterprise 2 2 2 2 1.75 35.0 
PS5 Adequacy of employment incentives 3 2 2 2 2.25 45.0 
 Individual Company average score at this Dimension  2 1.8 2.2 2 2 40.0 
Note: scale of 0-5, where 5 is the best 
 
According to table 4.13 shows that the policies support to the pharmaceutical industry 
got the lowest value of all the factors that contribute to the value chain of the 
pharmaceutical industry 40%, where there is very low tax incentives, except Beit Jalla 
which benefits from some tax incentives "the low of encouraging investment" but it ends 
by 31/12/2014 according the their discloser info 2013, and there is a low inward 
investment incentives,  inadequate of legal system support, and employment incentives.  
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4.4 Companies financial analysis  
The researcher in this section had analysed the competitiveness of the four 
pharmaceutical companies according to their profits, market share (sales) as (Porter, 
1990) , and the operating profit, (Hsu et al., 2013).  In order to achieve the best 
reliability for the results of the research and to compare it with the results of 
competitiveness gained from the survey. The results are as follow. 
Table 4.14.  Companies' financial information. 
 
No. Manufacturer # of 
employees 
Sales* Gross income 
"profit" 
Operating 
profit 
Net 
income 
Operating 
profit % of  
the total profit 
12** 13 12 13 12 13 12 13 12 13 
1 BPC  283 22936 25123 9740 10200 5741 5183 4976 5480 59 51 
2 JPC 150 18072 22018 8316 10514 631 2358 195 2248 8 22 
3 PHARMACARE  277 15364 16221 4754 6484 341 447 2027 1688 7 7 
4 Beit Jalla 159 7981 8876 2552 2918 886 863 810 821 35 30 
*. Sales are in thousands of dollars. 
**.  Years 2012 and 2013 
Source: companies closer declarations. (2013)  "Palestine capital market authority". 
 
Table 4.14 shows all of the financial information of the four companies, which are the 
sales, gross income, net income, and operating profits, such information are illustrated 
and demonstrated more clearly in the following sections. 
 
4.4.1 Market share analysis 
The following figure shows the revenue of each company "sales". In the years 2012, 
and 2013 in 1000's USD. 
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Figure 4.1: firms' sales in 2012, 2013 
Source: Table 4.14 
According to the (PNA, 2011) the domestic manufacturers held 50 % of the market 
share by the value produced, and this market share have been distributed between 
these manufacturers as follow in figure 4.2. 
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Figure 4.2: local market share distribution between the local manufacturers. 
Source: Table 4.14 
From the table 4.13 and figure 4.2 it is clear that Birzeit company hold the most market 
share, and then comes JPC, Pharmacare, and Beit Jalla.. so according to (Porter, 
1990), (Hsu et al., 2013), and (SDAG, 2001), the Birzeit company is the most 
competitive among the others. 
4.4.2 Profitability analysis 
The following figure 4.3 shows the profit of each company. In the years 2012, and 2013 
in 1000's USD. 
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Figure 4.3: pharmaceutical companies profits is 2012, 2013. 
Source: Table 4.14 
Figure 4.3 shows that Birzeit Company had the most profit among the others in 2012, 
while the Jerusalem Company had got the most profits in 2013 but a little exceeded the 
Birzeit Company with 2.99% which makes them both in the top of the companies related 
to their achieved profits. Therefore the competitiveness of the companies could be 
ordered from high to low according to the profits achieved as follow: BPC, JPC, 
Pharmacare, and Bet Jalla. 
4.4.3 Operating profits analysis 
The following figure 4.4 shows the operating profit of each company. In the years 2012, 
and 2013 in 1000's USD. 
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Figure 4.4: the operating profit of the companies in 2012, 2013. 
Source: Table 4.14 
The figure 4.4 shows that Birzeit Company has the best operating profit, among the 
other companies, while Jerusalem Company which has almost the same profit with BPC 
had operating profits so much below BPC, which means its operating costs, are so 
much higher. On other hand Pharmacare and Bet Jalla got operating profits below 
1,000,000 USD. In order to understand the operating profits more clearly, the 
researcher had made them as a percentage of the profits "gross income". Where the 
values are as follow in figure 4.5. 
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Figure 4.5: operating profits percentages in years 2012, 2013. 
Source: Table 4.14 
The figure 4.5 illustrates the meaning of operating profits more clearly according to (Hsu 
et al., 2013), where it shows that BPC got the higher percentage, which means it has 
the best profitability, and lower operating costs. Where Beit Jalla Company comes next 
which means that related to its profits size, its profitability is better than Jerusalem, and 
Pharmacare companies. Therefore the Birzeit Company has the best profitability 
competitiveness, and then comes Beit Jalla, Jerusalem, and Pharmacare, respectively. 
From the above analysis the researcher found that Birzeit had got the best 
competitiveness, because it got the best results in the market share, profits, and 
operating profits, while the next one was Jerusalem company "JPC", and the third 
Pharmacare, and finally is Beit Jalla, but the researcher found that in JPC, Pharmacare 
they have so much high costs which lower their competitiveness status. 
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4.5 Answers of the research question. 
Q1:  To what extent does the Palestinian pharmaceutical industrial sector 
implement the clustering concept? 
 
From the results shown above in the first section of data analysis, which is the 
assessment of the clustering situation of the pharmaceutical companies, and through 
reviewing the (Porter, 1990) definition of clusters as a group of companies, specialized 
suppliers, service providers, firms in related industries, in particular fields that are co-
located in a specific geographic region and linked by interdependencies in providing a 
related group of products, it is clear that the term of clusters exists if three conditions 
are available, which are: 
 Firms in related industries, in a particular field. 
 They are co-located in a specific geographic region. 
 They are linked by interdependencies. 
The Palestinian pharmaceutical companies are all working in the same field, which is 
the pharmaceutical industry, which means that they apply to the first condition. And 
according to the second condition, three of them which are: BPC, JPC, and PLC exist in 
a small area which is Ramallah city, which mean that they apply to the second 
condition, just BJPC which exists in Beit Lehem don‘t apply to this condition due to its 
existence in another city. Finally the third condition is that the firms should be linked by 
interdependences in providing a related group of products, where this condition which 
ensures the horizontal relationships and collaborative actions between firms is totally 
missing, because of the absence of such interdependences between firms due to the 
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high competition between them, even there is a union of pharmaceutical industries in 
Palestine, but its role approximately goes to zero, where it hasn‘t any tangible effect on 
the industry and this is clear in the dimension 11 which is support activities.  
This leads to say that the Palestinian pharmaceutical industry doesn‘t implement the 
clustering concept, because of the absence of the joint activities that collect them, 
where every one source from his special sources, and has its distribution network, and 
there are no tangible effects of agencies, or associations that make them work together, 
etc.  
Q2 To what extent does The Palestinian pharmaceutical industrial sector play as 
a potential cluster? 
Based on the distinctions between cluster types that have been pointed by (Mytelka & 
Farinelli, 2000) which are: spontaneous grouping of firms, suppliers, and public sector 
around a growth industry, and those spontaneous clusters could be informal, organized, 
and innovative, and the other type is a constructed cluster such as industrial parks and 
incubators. The Palestinian pharmaceutical companies are potential of the first category, 
where they are not a constructed cluster, but they are a group of firms, and related 
industries that produce the same types of products, and exist in a small geographic 
area.  
While according to (Aylward & Glynn, 2005), the Palestinian pharmaceutical companies 
as a spontaneous cluster couldn‘t be described as an informal of organized cluster, that 
is because these types are low innovative and for small and medium companies. But 
the most appropriate category that is applicable to the pharmaceutical companies is the 
innovative cluster, which has large firms, a wide skill level range, where each company 
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has a Ph.D., M sc., B sc., diploma, high school, and below high school degrees. And 
these firms have medium linkage between them, such as MOH, MONE, and the 
pharmaceutical union. And have some exports, but have also a poor cooperation.  
Another thing and based on the  
This description makes the Palestinian pharmaceutical companies so much potential to 
the innovative spontaneous cluster definition. (Aylward & Glynn, 2005), (Mytelka & 
Farinelli, 2000) since the companies are all a related firms, producing a related groups 
of products, located in same geographic area, which is not constructed areas as in the 
industrial parks situation, and they all work in an innovative industry.  
 
 
Q3: How does the implementation of clustering concept enhance the 
competitiveness of the pharmaceutical companies? 
To answer this question the researcher had made a comparison between 
companies based on their competitive advantages, and their individual clustering 
situation, while the results show that BPC has the most competitiveness among others 
due to its better vertical relationship. Where the advantages were in the dimensions of: 
 Firm's infrastructure, which is the results of its size which made it to work as a 
complete cluster and have a very strong vertical relationships, such as its 
complementary action by acquiring Palestine for printing and publication 
company, marketing and sales department which deals with every customer 
directly, and finally the technological requirements that are needed to acquire the 
special certificates needed for the industry.  
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 Outbound logistics. Where BPC had got this advantage through its strategic 
relationship with one of the best transportation companies, which is Albarq 
Company which enabled the company to have a fast response to every order in 
the West Bank. 
 Inbound logistics. Due to its big stores, and advanced control on it, where BPC 
had a contract with Bisan Company the IT specialists control its stores and 
inventory. 
However BPC had the best vertical relationships which enabled it to get the best 
competitive advantage. But by looking to the data collected on the pharmaceutical 
companies, the researcher found that the companies don‘t have horizontal 
relationships, or even any resource sharing relationships, and all of the companies 
don‘t have a good advantage in the following dimensions 
1- Technology development 
2- Procurement. 
3- Support activities. 
4- And policy support. 
 
(SDAG, 2001) Illustrated that clusters lead to innovation because of its core 
characteristics of close collaboration and close competition, whereas cluster develops a 
new demand for new types of products and services will be created. This is so 
applicable to the Palestinian pharmaceutical companies, where all of them are looking 
to expand their market share through new products, and by entering new markets. They 
have a good example of joint marketing through the company "care" which work with all 
116 
 
the manufacturers to market in Bella Russia, on the contrary BPC, and JPC are building 
in Algeria to be able to sell there, but they was able to build one manufacture and sell 
together. So clustering can help them entering new markets with less cost. 
 
Another thing, they could have a common firms for their supplies in plastic, 
printing, transportation, and even in R&D and testing their new formulas, the clinical 
testing. And they could become a force to establish a common local supplier for the raw 
materials, where right now each company needs a license for every material they need, 
but if there is local supplier, then these certification could be saved, and a single service 
window will be available. Many other action could be done collectively and 
collaboratively in order to increase innovation, profits, decrease cost, technology 
transfer, etc. (Schmitz, 1995). 
So clustering will enhance the competitiveness of the pharmaceutical companies 
through horizontal relationships, resource sharing, and common interdependences that 
will help all of them, such as: 
 Establish a domestic supplier for the raw material "collaborative sourcing", which 
will help them not to delay their orders in the event of waiting not available raw 
materials. 
 Effective union or cluster management, which will help improving the negotiation 
power with the decision makers, to enhance the related legislations, such as 
enabling a domestic supplier of raw materials, and clinical testing. 
 Establishment of shared companies, or even shared trademarks "collaborative 
marketing" which will enable more access to the international markets, instead of 
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separately entrance to the markets which will cost more to the companies, such 
as BPC, and JPC entrance to Algerian market, and PLC to the Iraqi market. 
 Establishment of local research and development center, which will offer the 
clinical testing for the new products, and may offer also producing and 
registration of new products. 
 Establishment of firm which will manufacture some of the starting raw materials. 
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4.6 cluster map 
 
Figure 4.6 : Cluster map 
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5. 1 introduction  
The researcher has measured Firm Infrastructure, HR Management, Technology   
Development, Procurement, Inbound Logistics, Operations, Outbound Logistics, 
Marketing and Sales, Service, Profit Margin, Support Activities, and Policy Support for 
the four surveyed companies. The researcher has calculated the average percentage 
for all the dimensions for each company, in order to know the strength points which give 
the firms its competitive advantages and the weakness points in order to know what is 
needed to achieve a better competitiveness for the companies, and the industry as a 
whole. Then the researcher compared the current situation in all factories in regards to 
all the dimensions. 
Table 5.1: Overall score for all the companies. 
Company 
Score 
Overall Score 
Out of 5 Percentage % 
Beit Jala 3.01 60.2 
62.45 
Birzeit 3.32 66.4 
Jerusalem 3.08 61.6 
Dar Al Shifa 3.08 61.6 
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Figure 5.1: Overall Score for surveyed companies 
 
Table 5.1 shows the overall score for the surveyed companies. Jerusalem got 3.08, 
Birzeit got 3.32, Beit Jalla got 3.01, and Dar Al-Shifa scored 3.08. out of  5  
Table 5.1, and figure 5.1 show that there is no much difference between firms of 
Ramallah and Beit Jalla, which mean that the geographic location is not the most 
important competitive advantage for the pharmaceutical firms, where this could be due 
to the small area of the West Bank as a whole, and the distance between Ramallah and 
Beit Jalla is not so much far. However it is clear that the Birzeit Company got the best 
competitive advantages among the others as illustrated in the previous chapter, 
followed by Pharmacare, and Jerusalem, and finally Beit Jalla. This reflects that it has 
got the best competitiveness among the other companies. 
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But to know the factors that could enhance the competitiveness of the industry we need 
to investigate all of the factors separately, as in the following tables from 5.2 to 5.14.  
Table 5.2 shows the overall score for all the surveyed companies based on each 
dimension. For firm infrastructure the sore is 73.6%, for HR Management 67%, 
Technology Development got 63.8%, Procurement is 56.8%, for inbound logistics 
76.6%, their operations scored 77.40%, outbound logistics got 73%, Marketing and 
sales is 61.4% , services is 70%, profit margin is 40 % , support activities got 50% , and 
last policy support got 40%. 
 
Table 5.2: Overall score for all the companies. 
Dimensions  Score % 
Firm Infrastructure 73.6 
HR   Management 67 
Technology   Development 63.8 
Procurement 56.8 
Inbound Logistics 76.6 
Operations 77.4 
Outbound Logistics 73 
Marketing + Sales 61.4 
Service 70 
Profit Margin  40 
Support Activities 50 
Policy Support 40 
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Figure : 5.2 Overall Scores for deferent dimensions 
 
5.2  Firm infrastructure Dimension 
As shown in table 5.2 the overall average in firm infrastructure dimension is 73.6%, It is 
clear that all the companies scored relatively well in this dimension, and that goes to the 
natural of this industry which required a massive capital to get the required facility and 
production line. And it is a must for the pharmaceutical companies to get quality 
certificates. Moreover, all the manufacturers which were considered in this study got 
GMP certificate which force them to keep a good infrastructure with a very good control 
and monitoring system. However, it was notice that the membership in different 
associations does not bring a lot of benefit for the manufacturers, since their services 
are very limited and not up to expectations.  
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Table 5.3: Firm infrastructure 
 
 
 
 
5.3 HR Management Dimension 
As shown in table 5.4 the overall average in HR management dimension is 67%. This 
industry is mainly depend on graduate degree holders, with continues training to 
develop them and improve their productivity. All the companies with some minor 
differences keep a good care about their staff through different training programs. 
However, the recruiting process is still very traditional and need to be improved. 
 
Table 5.4: HR Management. 
HR Management 
Jerusalem Birzeit Beit Jala Dar AL-Shifa 
66% 73.4% 60% 68% 
Firm infrastructure 
Jerusalem Birzeit Beit Jala Dar AL-Shifa 
76% 78% 66.15% 73.85% 
125 
 
 
5.4 Technology Development Dimension. 
The overall average in this dimension is 63.8%. Productivity, cost saving and innovation 
depend mainly on technology development. However, because of the close, and limited 
market, the pharmaceutical companies had to invest in less productive machines and 
not up to date technology.  
Table 5.5 : Technology Development. 
Technology Development 
Jerusalem Birzeit Beit Jala Dar AL-Shifa 
65% 70% 55.0% 65.0% 
 
 
5.5 Procurement Dimension. 
The overall average in this dimension is 56.8%. Procurement process is very 
complicated for the pharmaceutical companies; it needs permission every time under 
the company‘s name. Moreover, the material should pass the approval of Israeli control, 
which make their production flow very sensitive to the political situations. Moreover, 
Israeli policy is clearly in favour of the Israeli manufacturers who are one of the main 
competitors of the local manufacturers over the local market. 
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Table 5.6: Procurement. 
Procurement 
Jerusalem Birzeit Beit Jala Dar AL-Shifa 
56.7% 60.0% 56.7% 53.3% 
 
5.6 Inbound Logistics Dimension. 
The overall average in this dimension is 76.6%. As it was explained in the Procurement 
process, the pharmaceutical companies try to overcome this challenge and to benefit 
from bulk purchasing, they made a quite big storage for the raw materials. Moreover, 
GMP practices required a clear separation between storage and production section, and 
to have a separate storage for quarantined returned goods. 
Table 5.7: Inbound Logistics. 
Inbound Logistics 
Jerusalem Birzeit Beit Jala Dar AL-Shifa 
76% 80% 73.4% 76.6% 
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5.7 Operations Dimension. 
The overall average in this dimension is 77.4%. Most of the pharmaceutical 
manufacturers utilize over 80% of their production capacity with relatively good 
efficiency. However, they work for one shift only which result from the small market they 
got. Generally their premises are kept in a very clean and arranged situation. Again the 
GMP regulation was clearly reflected in the companies‘ operations.  
 
Table 5.8: Operations. 
Operations 
Jerusalem Birzeit Beit Jala Dar AL-Shifa 
74.6% 78.2% 76.4% 80% 
 
5.8 Outbound Logistics Dimension. 
The overall average in this dimension is 73%. To meet with the customers‘ needs, and 
to deliver the products as soon as they ordered, the pharmaceutical companies usually 
keep finished products in their storage, and Most of the pharmaceutical manufacturers 
have their own distributors with a good distribution channels. Moreover, the strong 
competition between the manufacturers, and the natural of the products, force them to 
quickly respond to the orders otherwise the customers will go to another supplier. 
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Table 5.9: Outbound Logistics. 
Outbound Logistics 
Jerusalem Birzeit Beit Jala Dar AL-Shifa 
72.0% 80.0% 72.0% 68.0% 
 
 
5.9 Marketing & Sales Dimension.     
The overall average in this dimension is 61.40%. Mostly the pharmaceutical 
manufacturers depend on free sampling, face to face promotions, and discount price for 
marketing their products.  
Table 5.10: Marketing & Sales. 
Marketing & Sales 
Jerusalem Birzeit Beit Jala Dar AL-Shifa 
60.0% 65.2% 60.9% 59.1% 
 
5.10 Service Dimension.     
The overall average in this dimension is 70.00%. The pharmaceutical manufacturers 
provide all possible services to their customers, such as, brochures, posters to help 
them market their products, and guarantees. 
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Table 5.11: Service. 
Service 
Jerusalem Birzeit Beit Jala Dar AL-Shifa 
65% 80% 70% 65% 
 
5.11 Profit Margin Dimension.     
The overall average in this dimension is 40%. Although some manufacturers have some 
unique products, but most of them have a lot of common products. That why they are 
forced to compete in prices in many cases. Which leave them with a very minor profit 
margin. 
Table 5.12: Margin. 
Service 
Jerusalem Birzeit Beit Jala Dar AL-Shifa 
40% 40% 40% 40% 
 
5.12 Support Activities Dimension.     
The overall average in this dimension is 50.0%. Usually the suppliers don‘t provide any 
services to the pharmaceuticals companies. No government support comparing to what 
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the importers get. Registration for new drugs needs long procedures comparing to the 
imported products.    
Table 5.13: Support Activities. 
Support Activities 
Jerusalem Birzeit Beit Jala Dar AL-Shifa 
44% 56% 48% 48% 
 
 
5.13 Policy Support Dimension.     
The overall average in this dimension is 40%. Israeli politics agenda to inflict the 
pharmaceutical industry with the Israeli industries, unfair competition in the market, the 
difficulty of importing raw materials. And the weak incentive that the Palestinian 
authority give to them .All this participated in making the score relatively low. 
Table 5.14: Policy Support. 
Policy Support 
Jerusalem Birzeit Beit Jala Dar AL-Shifa 
40% 36% 44% 40% 
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From the data displayed above it is clear that the main disadvantage is the low of 
policies support, support activities, the profit margin is low but this is due to the 
manufacturing of generic drugs, and not have special patents. Where this is not a 
weakness because the annual growth rate of total pharmaceutical market value is 7 %, 
while that of the generic pharmaceuticals market alone is 70 %.  And the market share 
of the generic drugs is 50% (PNA, 2011). While the other factor which is a disadvantage 
is the procurement, that is because it is not easy change the suppliers, and they all are 
from outside and shall pass the Israeli approval to get it. 
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5.14 Conclusions. 
 
Although there are slightly disparity at the companies‘ results. However, it was clear that 
they have common issue and face the same challenges. They scored relatively well in 
Firm Infrastructure, Inbound Logistics, Operations, Outbound Logistics, Marketing & 
Sales. However, they face some serious challenges in the other aspects. The following 
model summarizes the entire factors according to Porter diamond model to analyse the 
cluster competitiveness for pharmaceutical cluster.  
Where this strengths, and weakness of the cluster have been summarized from the data 
of survey, interviews, and previous studies by the general directorate of pharmacy, 
(PNA, 2011). 
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Strengths: 
 National exporting strategy. 
 Free trade agreements. 
 National policy toward supporting local 
industries.  
 Local government prioritizes this 
industries 
 Accurate National sector data are 
available 
Weaknesses: 
 High labour costs / taxes + energy costs. 
 Economic + political instability 
 Low public + private sector co-operation. 
 
FIRM STRATEGY + 
RIVALRY 
DEMAND 
CONDITIONS 
FACTOR 
CONDITIONS 
RELATED + SUPPORTING 
ORGANIZATIONS 
GOVERNMENT 
CHANCES  FOR 
COLLABORATION 
Strengths: 
 Strong regional history of pharmaceutical products. 
 Good outbound logistic. 
 Potential to improve quality and productivity by getting 
certificate of GMP ,  entering new markets. 
 Fast delivery to market remains important to buyers 
 High institutionalization levels in the firms 
 Well technical know-how and innovation. 
Weaknesses: 
 No some sub-sector and cross sub-sector co-operation 
occurring. 
 Low flexibility of productions. 
 High competition from imported products. 
 limited marketing / promotion activity 
 Low trust / co-operation between cluster members. 
 Firms have low ability to invest in innovation and 
development  R&D. 
 Labour costs. 
 No R&D center 
 
 
 
 
Strengths: 
 Increasing population 
 Several emerging markets 
(and many are nearby) 
 Growing demand for niche / 
premium products 
 Competitive price comparing 
to imported products.  
 Availability of quality 
standards. 
 High  production capacity  
 
 
Weaknesses: 
 General economic situation  
 High Israeli reliance. 
 Upward price pressure on 
input costs 
 Only few markets is open for 
export. 
•High dependency on Israeli 
regulations.. 
Strengths: 
 Existing 
supporting 
organization 
specialized for this 
industry 
 Sector specific 
educational 
training are 
available 
Palestine. 
Weaknesses: 
 Data not 
communicated to 
cluster. 
 NO National R&D 
centres. 
 No local cluster 
association  
 Weak relationship 
between 
members. 
 
 
Strengths: 
 Workforce availability 
 fair transport 
network 
 Free trade agreement  
with European 
markets 
 Relatively close. 
 
Weaknesses: 
 No availability of 
National data  
 Low skills update. 
 High fuel and thus 
transportation and 
power costs 
 Israeli occupation. 
 
Strengths: 
 Potential to develop supplier + other partnership 
relationships (via collaboration) 
 Potential to improve information availability  
 Supply chain management + efficiency 
improvements possible 
 Existence of supporting organizations (e.g. 
Chamber of commerce, Union of pharmaceuticals 
industries, businessman association, and Paltrade. 
 
Weaknesses: 
 Limited services available from local BSO. 
 Unsupportive cluster for collaboration and 
clustering.  
 Absents of Industry + cluster trend towards 
strategic co-operation, consolidation + clustering. 
 limited suppliers + vertical integration of the 
supply chain . 
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5.15.1 Conclusion One: 
According to the interviews currently the pharmaceutical companies do not apply any 
clustering action, except in the case of the marketing company ―Care‖ which slightly 
involve some kind of clustering relationships, which is a collaborative marketing in Bella 
Russia, where this is actually not done by the companies or even directed by any one of 
them, on the contrary, this was done by the care company which aims to sell Palestinian 
medicines there.  
5.15.2 Conclusion two: 
The model that the researcher suggested in the previous chapter in the suggested 
cluster map shows that those companies will overcome those challenges and increase 
their competitiveness by forming a cluster initiative. They are a very strong potential 
cluster for the following factors:   
 The number of companies is relatively small, with geographical proximity 
between them, and they have a high cultural cohesion factors.  
 They have common threats and/or challenges. 
 Potential for commercial development and potential of HR development.  
 Potential for improving processes and products, by make every firms to have a 
number of products that it produce alone where this will enhance its 
competitiveness by minimizing time of lines setup, and focus on these products,  
 Potential to optimize the supply chain. By establishing a joint supplier in the 
region, and a joint marketer, and a research and testing center. 
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 Common needs for public strategies and regulations to support the sector, such 
as allowing the clinical testing, and make incentives to support exports. 
 Opportunities to improve the incentive framework for the activity. 
 Opportunities and potential impact of local partnerships with public institutions. 
 Common needs and challenging in accessing financial and non-
financial services. Because the investment in this sector needs high capital to be 
injected for new lines. And there is no support for the long term investment in 
Palestine,  
 Attractiveness for new external investment, especially the related industries, like 
packaging, transportation, etc.  
 There is feasibility of a cluster initiative in term of cost reduction and improving 
production effectiveness. Where this is could be by joint marketing such as invest 
in Algeria in one company for all of the companies, instead of invest in many 
companies as occur with JPC, and BPC, and specialization of certain medicines 
types which will reduce the cost of production lines setup which consumes so 
much time and money to change from a medicine type to another.   
 Local Public sector is encouraging private sector to work as cluster. Where there 
is currently a project from the French Government to support clusters in 
Palestine, and this project is done in collaboration with them Ministry of National 
Economy MONE, where they built their capitalization unit for clustering. Interview 
with the contact of cluster in MONE. 
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5.15.3 Conclusion three: 
It is clear through the diagnosis carried out by the researcher that most of the local 
drugs are competitive in price, and in good quality however, some of the customers still 
don‘t trust the local products like the foreign products.  
Although the pharmaceutical manufacturers have good number strengths, such as their 
continuous development, high adaptability to change, availability of skilled labour, with 
competitive wages good quality products, with and significant local market share. 
The cluster‘s greatest obstacle is the absence of adequate R&D center, which is a key 
requirement for innovation. Nonetheless, there are opportunities for the cluster, 
including exports as well as increased local market share through greater participation 
in government tenders. Establishment of a national R&D center of the pharmaceutical 
cluster, use of local external common organization for recruiting, training, and 
developing Human resources .Divide the main products among the companies which 
will reduce the competition on those production line and let the individual company 
focus more on those products and invest in new products rather than competing on the 
exciting products. As well as import of raw material with bulk which will give them a 
better price. All in all, clustering will significantly improve the pharmaceutical companies.   
 
5.15.4 Conclusion four 
Clustering will enhance the relationship between the cluster members, and encourage 
them to undergo some collaborative and collective project which will enhance their 
competiveness. The current relation is very weak and do not promote sharing of 
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information, technology transfer, and co-production. However, with cluster approach 
those parameters will be possible, where there will be a support from the universities in 
R&D, testing, supplying the industry with a skilled workforce, and on the contrary the 
firms will supply the universities in training opportunities in the firms, and could supply 
some finance for the projects of the universities. 
On the other hand the firms will talk as a one part, and can get more power in front of 
the public sector, another thing they could have a shared brand for the cluster which 
ease for them the export and entering new markets, and lower the operating costs, 
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5.16 Recommendations  
Recommendation  
 The researcher recommends that the pharmaceutical should work as cluster as  
suggested in the cluster map in the previous chapter,  since it was proven by the 
research that it will increase the competitiveness by cost reduction, penetration of 
new markets, etc. 
 Business Support Organizations (BSOs) that related to the pharmaceutical 
industry such as chamber of commerce, and union of the pharmaceutical 
industries should play a major role in creating and organizing a cluster initiative 
for the pharmaceutical industry in order in expanding this industry to reach more 
and more markets, and attract more investments, which will reflect positively on 
the Palestinian economy, 
 The local government should encourage the pharmaceutical industries to work as 
a cluster and as a managed cluster through a set of incentive policies, such as 
tax incentive, building an R&D research and testing center, new regulation for the 
clinical testing, where this force all of the companies to work under the umbrella 
of the cluster, and take more collaborative projects, which would have a clear 
positive effect on the whole cluster. 
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Recommendations for future research  
 More  studies should be done in:  
o The effect of clustering using another clustering models other than porters 
one. 
o The effect of clustering on the competitiveness on other sectors which has 
firms smaller than the pharmaceutical firms. 
o The clustering of the high tech, and if the location have  an effect on the 
clustering. 
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Appendix 2 
Interview questions 
– open questions – 
O1 Why did you establish your business in this area?: 
History? Family? Other similar businesses in the locality? Access to raw materials? Other? 
. 
O2 What are the specific benefits of being located where you are? 
 
O3 What disadvantages do you face because of your location? 
 
O4 What links do you have with other businesses in your sector? 
 
O5 Do you have links to the Universities or R&D facilities in the governorate? 
 
O6 What do you consider to be your main competitive advantage?  
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O7 What are your major problems and barriers to  
 Increasing your competitiveness 
 Access more markets 
 
 
O8 If you could make three major changes to your business what would they be? 
 
O9 Do you have any investment plans for the next 12 months : 
. 
10 How do you see your competitors in the next 5 years 
 
11 Who are your main customers and markets? 
 
12 Who are your main competitors? 
 
 
13 What is the percentage of the total cost that is made up by the raw materials 
and components? 
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14 What do you understand about the Clustering? 
 
 
 
 
15 What Benefits do you think that the clustering will bring for your business? 
 
16 Currently, are you practicing any collaborative projects or assignments? (For example: 
Collaborative Marketing, Collaborative Purchasing, Collaborative Sub-contracting, 
Collaborative Training, Others?) 
 
 
 
 
 
